var title_f14_36_14912="Continuous wave Doppler MV area";
var content_f14_36_14912=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Calculation of mitral valve area from continuous wave Doppler",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The mitral valve area can be obtained from the continuous wave Doppler by calculating the time required for the opening pressure to reach one half of its value (P 1/2); this is called P 1/2 time and is calculated as shown. By regression analysis, a critically stenotic valve measuring 1 cm2 has a pressure half time of 220 ms; the valve area can be calculated as shown above.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_36_14912=[""].join("\n");
var outline_f14_36_14912=null;
var title_f14_36_14913="Acid fast staining of Nocardia";
var content_f14_36_14913=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acid fast staining of Nocardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 245px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nocardia spp, in contrast to Actinomyces spp, are positive by acid fast stain. The degree of acid-fastness is variable depending upon the mycolic acid content of the cell wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stanley W Chapman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_36_14913=[""].join("\n");
var outline_f14_36_14913=null;
var title_f14_36_14914="Grasping the vas during vasectomy";
var content_f14_36_14914=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Grasping the vas during vasectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The vas is elevated through the incision.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Clenney, TL, Higgins, JC. Vasectomy Techniques. American Family Physician 1999; 60:137. Copyright &copy;1999 Timothy Clenney, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_36_14914=[""].join("\n");
var outline_f14_36_14914=null;
var title_f14_36_14915="Activation TPO receptor";
var content_f14_36_14915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Activation of the TPO receptor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 453px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The TPO receptor has been proposed to exist as an inactive preformed dimer (left) with a proximal (HRD-1) and distal (HRD-2) hematopoietic receptor domain (HRD). Upon binding of thrombopoietin to the distal HRD-2, the receptor (right) conformation changes and a number of signal transduction pathways are activated that increase platelet production.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Illustration by Paulette Dennis. This research was originally published in Blood. Kuter, DJ. New thrombopoietic growth factors. Blood 2007; 109:4607. Copyright &copy; 2007 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_36_14915=[""].join("\n");
var outline_f14_36_14915=null;
var title_f14_36_14916="Chest xray pneumomediastinum";
var content_f14_36_14916=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    Chest radiograph showing pneumomediastinum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These AP and lateral views of the chest demonstrate pneumomediastinum (inferior arrows) with air tracking up into the soft tissues of the neck (superior arrows) in a patient with a tracheobronchial injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Pierre J Sasson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_36_14916=[""].join("\n");
var outline_f14_36_14916=null;
var title_f14_36_14917="Phentolamine: Pediatric drug information";
var content_f14_36_14917=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Phentolamine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"    see \"Phentolamine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/46/3812?source=see_link\">",
"    see \"Phentolamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6534231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      OraVerse&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F209218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Regitine&reg;;",
"     </li>",
"     <li>",
"      Rogitine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Alpha-Adrenergic Blocking Agent, Parenteral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Extravasation",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Diagnostic Agent, Pheochromocytoma",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vasodilator",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of alpha-adrenergic agonist drug extravasation: SubQ:",
"     <b>",
"      Note:",
"     </b>",
"     Total dose required depends on the size of extravasation; dose may be repeated if required. Infiltrate area of extravasation with a small amount (eg, 1 mL given in 0.1-0.2 mL aliquots) of a 0.25-0.5 mg/mL solution (made by diluting 2.5-5 mg in 10 mL of preservative free NS) within 12 hours of extravasation; in general, do not exceed 2.5 mg total; monitor blood pressure, especially when dose exceeds the recommended I.M./I.V. dose of 0.1 mg/kg",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"      see \"Phentolamine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of alpha-adrenergic agonist drug extravasation: SubQ:",
"     <b>",
"      Note:",
"     </b>",
"     Total dose required depends on the size of extravasation; dose may be repeated if required: Infants, Children, and Adults: Infiltrate area of extravasation with a small amount (eg, 1 mL given in 0.2 mL aliquots) of a 0.5-1 mg/mL solution (made by diluting 5-10 mg in 10 mL of NS) within 12 hours of extravasation; in general, do not exceed 0.1-0.2 mg/kg or 5 mg total;",
"     <b>",
"      Note:",
"     </b>",
"     Doses of &lt;5 mg total are usually effective; one",
"     <b>",
"      adult",
"     </b>",
"     case using a total  dose of 50 mg (given over 1 hour in 0.5 ml aliquots of a 1 mg/mL solution) for a large extravasation has been reported (Cooper, 1989).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Diagnosis of pheochromocytoma: I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 0.05-0.1 mg/kg/dose, maximum single dose: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hypertension (prior to surgery for pheochromocytoma): I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 0.05-0.1 mg/kg/dose given 1-2 hours before pheochromocytomectomy; repeat as needed to control blood pressure; maximum single dose: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 5 mg given 1-2 hours before pheochromocytomectomy; repeat as needed to control blood pressure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hypertensive crisis due to MAO inhibitor/sympathomimetic amine interaction: I.M., I.V.: Adults: 5-20 mg",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F209199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as mesylate: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as mesylate [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OraVerse&trade;: 0.4 mg/1.7 mL (1.7 mL) [contains edetate disodium; dental cartridge]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F209183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes injection, solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Treatment of extravasation: Infiltrate area of extravasation with multiple small injections of a diluted solution; use 27- or 30-gauge needles and change needle between each skin entry to prevent bacterial contamination and minimize pain; do not inject a volume such that swelling of the extremity or digit with resultant compartment syndrome occurs",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F209250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amiodarone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Papaverine.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1054923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reconstituted solution is stable for 48 hours at room temperature and 1 week when refrigerated",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diagnosis of pheochromocytoma; treatment of hypertension associated with pheochromocytoma or other causes of excess sympathomimetic amines; local treatment and prevention of dermal necrosis after extravasation of drugs with alpha-adrenergic effects (dobutamine, dopamine, epinephrine, metaraminol, norepinephrine, phenylephrine)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F209252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Phentolamine may be confused with phentermine, Ventolin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F209249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, flushing, hypertension (OraVerse&trade;), hypotension, orthostatic hypotension, tachycardia (OraVerse&trade;), bradycardia (OraVerse&trade;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache (OraVerse&trade;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus (OraVerse&trade;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting, diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site pain (OraVerse&trade;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (OraVerse&trade;), weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Pulmonary hypertension",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phentolamine or any component; renal impairment; coronary or cerebral arteriosclerosis; MI",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with gastritis, peptic ulcer; history of cardiac arrhythmias; MI, cerebrovascular spasm, and cerebrovascular occlusion may occur",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F209192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Alpha1-Blockers. Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F209195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13823798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some oral animal reproduction studies. Diagnosing and treating pheochromocytoma is critical for favorable maternal and fetal outcomes (Schenker, 1971; Schenker, 1982).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate, orthostasis; treatment of extravasation: site of extravasation, skin color, local perfusion",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Systemic: Competitively blocks alpha-adrenergic receptors to produce brief antagonism of circulating epinephrine and norepinephrine; reduces hypertension caused by alpha effects of catecholamines; also has positive inotropic and chronotropic effects on the heart",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     SubQ: Blocks alpha-adrenergic receptors and reverses vasoconstriction caused by extravasation of medications with alpha-adrenergic effects",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Within 15-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Immediate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Within 20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Within 2 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 30-45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Within 15-30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: 19 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 10% to 13% excreted in urine as unchanged drug",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1054936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When drugs with alpha-adrenergic effects extravasate, they cause local vasoconstriction which causes blanching of the skin and a pale, cold, hard appearance; SubQ phentolamine blocks the alpha-adrenergic receptors and reverses the vasoconstriction; the extravasation area should &ldquo;pink up&rdquo; and return to normal skin color following SubQ administration of phentolamine. Dobutamine primarily stimulates beta",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic receptors, but does possess alpha (and beta",
"     <sub>",
"      2",
"     </sub>",
"     ) adrenergic effects; the alpha-adrenergic effects (vasoconstriction) may be seen when dobutamine extravasates (since high concentrations of dobutamine would be present locally); although infrequent, cases of dermal necrosis from dobutamine extravasation have been reported; thus, phentolamine may help prevent dermal necrosis following dobutamine extravasations (Hoff, 1979; MacCara, 1983). Injection contains mannitol 25 mg/vial",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cooper BE, \"High-Dose Phentolamine for Extravasation of Pressors,\"",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1989, 8(10):689.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/36/14917/abstract-text/2805622/pubmed\" id=\"2805622\" target=\"_blank\">",
"        2805622",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flemmer L and Chan JS, \"A Pediatric Protocol for Management of Extravasation Injuries,\"",
"      <i>",
"       Pediatr Nurs",
"      </i>",
"      , 1993, 19(4):355-8, 424.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/36/14917/abstract-text/8414723/pubmed\" id=\"8414723\" target=\"_blank\">",
"        8414723",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoff JV, Peatty PA, and Wade JL, &ldquo;Dermal Necrosis From Dobutamine,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1979, 300(22):1280.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/36/14917/abstract-text/431702/pubmed\" id=\"431702\" target=\"_blank\">",
"        431702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      MacCara ME, &ldquo;Extravasation: A Hazard of Intravenous Therapy,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1983, 17(10):713-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/36/14917/abstract-text/6628223/pubmed\" id=\"6628223\" target=\"_blank\">",
"        6628223",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Siwy BK and Sadove AM, \"Acute Management of Dopamine Infiltration Injury With Regitine,\"",
"      <i>",
"       Plast Reconstr Surg",
"      </i>",
"      , 1987, 80(4):610-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/36/14917/abstract-text/3659173/pubmed\" id=\"3659173\" target=\"_blank\">",
"        3659173",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Subhani M, Sridhar S, and DeCristofaro JD, \"Phentolamine Use in a Neonate for the Prevention of Dermal Necrosis Caused by Dopamine: A Case Report,\"",
"      <i>",
"       J Perinatol",
"      </i>",
"      , 2001, 21(5):324-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/36/14917/abstract-text/11536027/pubmed\" id=\"11536027\" target=\"_blank\">",
"        11536027",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thigpen JL, \"Peripheral Intravenous Extravasation: Nursing Procedure for Initial Treatment,\"",
"      <i>",
"       Neonatal Netw",
"      </i>",
"      , 2007, 26(6):379-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/36/14917/abstract-text/18069429/pubmed\" id=\"18069429\" target=\"_blank\">",
"        18069429",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zenk KE, \"Management of Intravenous Extravasations,\"",
"      <i>",
"       Infusion",
"      </i>",
"      , 1981, 5:77-9.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12700 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-CF9877BBA9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_36_14917=[""].join("\n");
var outline_f14_36_14917=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6534231\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209218\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054927\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444745\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054921\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209199\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209183\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054931\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209250\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054923\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054930\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209252\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209249\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054935\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054920\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299867\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209192\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209195\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13823798\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054926\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054919\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054933\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054934\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054936\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12700\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12700|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=related_link\">",
"      Phentolamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/46/3812?source=related_link\">",
"      Phentolamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_36_14918="Membranous VSD long axis color still frame";
var content_f14_36_14918=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Membranous VSD long axis color still frame",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Long axis still frame from a two-dimensional transthoracic echocardiogram with and without color flow mapping. In the left hand panel, color flow mapping demonstrates the jet of left-to-right flow crossing the septum just apical to the aortic annulus. The ventricular septal defect (VSD) is shown without color flow mapping in the right hand panel (arrow).",
"    <div class=\"footnotes\">",
"     LA: left atrium; LV: left ventricle; RV: right ventricle; AO: aorta; arrow: VSD.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_36_14918=[""].join("\n");
var outline_f14_36_14918=null;
var title_f14_36_14919="Aliskiren and amlodipine: Drug information";
var content_f14_36_14919=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aliskiren and amlodipine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/12/21701?source=see_link\">",
"    see \"Aliskiren and amlodipine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F11370416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11372750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tekamlo&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10573376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antianginal Agent;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker, Dihydropyridine;",
"     </li>",
"     <li>",
"      Renin Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F11370514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Dosage must be individualized. Combination product may be used as initial therapy or substituted for individual components in patients currently maintained on both agents separately or in patients not adequately controlled with monotherapy (using one of the agents or an agent within same antihypertensive class).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Initial therapy:",
"     </i>",
"     Aliskiren 150 mg and amlodipine 5 mg once daily; dose may be titrated at 2- to 4-week intervals; maximum recommended daily doses: Aliskiren 300 mg; amlodipine 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Add-on therapy:",
"     </i>",
"     Initiate by adding the lowest available dose of the alternative component (aliskiren 150 mg or amlodipine 5 mg); dose may be titrated at 2- to 4-week intervals; maximum recommended daily doses: Aliskiren 300 mg; amlodipine 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Replacement therapy:",
"     </i>",
"     Substitute for the individually titrated components",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Prior to initiation, correct hypovolemia and/or closely monitor volume status in patients on concurrent diuretics during treatment initiation.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F11370527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Use of lower initial doses should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F11370516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: Initial: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Initial: No dosage adjustment may be necessary (Vaidyanathan, 2007 [aliskiren]); however, risk of hyperkalemia and progressive renal dysfunction may occur with aliskiren; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     ESRD (requiring hemodialysis): Initial: No dosage adjustment may be necessary (Khadzhynov, 2012 [aliskiren]); however, risk of hyperkalemia is increased with chronic aliskiren therapy; use with extreme caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F11370515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mild-to-severe: Use with caution and titrate slowly; amlodipine elimination prolonged; lower initial dose should be considered (possibly requiring use of the individual agents).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F11371544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tekamlo&trade; 150/5: Aliskiren 150 mg and amlodipine 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tekamlo&trade; 150/10: Aliskiren 150 mg and amlodipine 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tekamlo&trade; 300/5: Aliskiren 300 mg and amlodipine 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tekamlo&trade; 300/10: Aliskiren 300 mg and amlodipine 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F11370419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11370528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer at the same time daily. May take with or without a meal, but consistent administration with regards to meals is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10573377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension, alone or in combination with other antihypertensive agents",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F11370430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequencies reported with combination product. See individual monographs for additional adverse effects reported with each agent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%: Cardiovascular: Peripheral edema (6% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Angioedema, BUN increased, creatinine increased, hyperkalemia, hypotension",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11370425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to aliskiren, amlodipine, or any component of the formulation; concomitant use with an ACE inhibitor or ARB in patients with diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11370426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angina/MI: Increased angina and/or MI have occurred with initiation or dosage titration of dihydropyridine calcium channel blockers, including amlodipine. Reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease, especially in the absence of concurrent beta-blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperkalemia: May occur (rarely) during monotherapy; risk may increase in patients with predisposing factors (eg, renal dysfunction, diabetes mellitus or concomitant use with ACE inhibitors, ARBs, NSAIDs, potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity: Anaphylaxis and angioedema have been reported. Since the effect of aliskiren on bradykinin levels is unknown, the risk of kinin-mediated etiologies of angioedema occurring is also unknown. Use with caution in any patient with a history of angioedema (of any etiology) as angioedema has been observed (rarely) with aliskiren use. Discontinue immediately following the occurrence of anaphylaxis or angioedema; do not readminister. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive, early, and appropriate management is critical.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypotension: During the initiation of therapy, symptomatic hypotension may occur (rarely), particularly in patients with an activated renin-angiotensin system (ie, volume- or salt-depleted patients). Prior to initiation, correct hypovolemia and/or closely monitor volume status in patients on concurrent diuretics during treatment initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Peripheral edema: The most common side effect of amlodipine is peripheral edema; occurs within 2-3 weeks of starting therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use amlodipine with extreme caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes mellitus: Use (monotherapy or combined with ACE inhibitors or ARBs) in patients with type 2 diabetes mellitus has demonstrated an increased incidence of renal impairment, hypotension, and hyperkalemia; use is contraindicated in patients with diabetes mellitus who are taking an ACE inhibitor or ARB.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use amlodipine with caution in patients with severe hepatic impairment; may require lower starting dose and slower titration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use amlodipine with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution or avoid in patients with deteriorating renal function or low renal blood flow (eg, renal artery stenosis, severe heart failure); may increase risk of developing acute renal failure and hyperkalemia. Concomitant use of aliskiren with an ACE inhibitor or ARB may increase risk of developing acute renal failure and should be avoided in patients with GFR &lt;60 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; High potential for interactions: Avoid concurrent use of aliskiren with strong inhibitors of P-glycoprotein (eg, cyclosporine, itraconazole).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Exposure to amlodipine is increased in the elderly; consider use of a lower initial dose (may necessitate use of individual agents).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10814872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Aliskiren may enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors.  Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Aliskiren may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers.  Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Calcium Channel Blockers (Dihydropyridine). Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Furosemide: Aliskiren may decrease the serum concentration of Furosemide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the serum concentration of Aliskiren. Management: Avoid concomitant use of aliskiren and grapefruit juice. Separation of aliskiren and grapefruit juice administration by several hours may reduce the chance for interaction. Monitor for decreased aliskiren levels/effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of AmLODIPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroprusside: Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren. Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: AmLODIPine may increase the serum concentration of Simvastatin.  Management: Avoid the concurrent use of amlodipine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day (for adults).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F11370461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: High-fat meals decrease absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Avoid herbs with",
"     <i>",
"      hypertensive",
"     </i>",
"     properties (bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng [American], kola, licorice). Avoid herbs with",
"     <i>",
"      hypotensive",
"     </i>",
"     properties (black cohosh, California poppy, coleus, garlic, goldenseal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F11370421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11370422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F11370423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11370424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F11370541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food, however, a high-fat meal reduces absorption. Consistent administration with regards to meals is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tekamlo Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150-5 mg (30): $118.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150-10 mg (30): $118.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300-5 mg (30): $149.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300-10 mg (30): $149.58",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11370542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; serum potassium, BUN, serum creatinine",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13733201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Rasilamlo (AR, CH, CZ, EE, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F11370464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Aliskiren: Direct renin inhibitor, resulting in blockade of the conversion of angiotensinogen to angiotensin I. Angiotensin I suppression decreases the formation of angiotensin II (Ang II), a potent blood pressure-elevating peptide (via direct vasoconstriction, aldosterone release, and sodium retention). Ang II also functions within the Renin-Angiotensin-Aldosterone System (RAAS) as a negative inhibitory feedback mediator within the renal parenchyma to suppress the further release of renin. Thus, reductions in Ang II levels suppress this feedback loop, leading to further increased plasma renin concentrations (PRC) and subsequent activity (PRA). This disinhibition effect can be potentially problematic for ACE inhibitor and ARB therapy, as increased PRA could partially overcome the pharmacologic inhibition of the RAAS. As aliskiren is a direct inhibitor of renin activity, blunting of PRA despite the increased PRC (from loss of the negative feedback) may be clinically advantageous. The effect of aliskiren on bradykinin levels is unknown.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Amlodipine: Inhibits calcium ion from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina. Amlodipine directly acts on vascular smooth muscle to produce peripheral arterial vasodilation reducing peripheral vascular resistance and blood pressure.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11370466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Khadzhynov D, Slowinski T, Lieker I, et al, \"Pharmacokinetics of Aliskiren in Patients With End-Stage Renal Disease Undergoing Haemodialysis,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2012, 51(10):661-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/36/14919/abstract-text/23018529/pubmed\" id=\"23018529\" target=\"_blank\">",
"        23018529",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Littlejohn TW 3rd, Trenkwalder P, Hollanders G, et al, \"Long-Term Safety, Tolerability and Efficacy of Combination Therapy With Aliskiren and Amlodipine in Patients With Hypertension,\"",
"      <i>",
"       Curr Med Res Opin",
"      </i>",
"      , 2009, 25(4):951-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/36/14919/abstract-text/19257800/pubmed\" id=\"19257800\" target=\"_blank\">",
"        19257800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vaidyanathan S, Bigler H, Yeh C, et al, &ldquo;Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskerin Alone and in Combination with Irbesartan in Renal Impairment,&rdquo; Clin Pharmacokinet, 2007, 46(8):661-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/36/14919/abstract-text/17655373/pubmed\" id=\"17655373\" target=\"_blank\">",
"        17655373",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15627 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-062E1C4994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_36_14919=[""].join("\n");
var outline_f14_36_14919=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11370416\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11372750\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10573376\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11370514\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11370527\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11370516\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11370515\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11371544\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11370419\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11370528\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10573377\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11370430\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11370425\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11370426\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298707\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10814872\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11370461\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11370421\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11370422\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11370423\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11370424\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11370541\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322865\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11370542\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13733201\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11370464\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11370466\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15627\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15627|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/12/21701?source=related_link\">",
"      Aliskiren and amlodipine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_36_14920="Stroke risk medical treatment";
var content_f14_36_14920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F71761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F71761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Predicted five-year risk of ipsilateral ischemic stroke in patients with recently symptomatic carotid stenosis on medical treatment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 612px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Derived from Cox model based on five clinically important patient characteristics in men and women. Stroke/TIA/Ocular refers to the most severe symptomatic ipsilateral ischemic event in the past six months: Stroke&gt; Cerebral TIA&gt; Ocular events only.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rothwell, PM, Mehta, Z, Howard, SC, et al. From subgroups to individuals: general principles and the example of carotid endarterectomy. Lancet 2005; 365:256. Copyright &copy; 2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_36_14920=[""].join("\n");
var outline_f14_36_14920=null;
var title_f14_36_14921="Prevention of firearm injuries in children";
var content_f14_36_14921=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of firearm injuries in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/36/14921/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/36/14921/contributors\">",
"     Anne C Gill, DrPH, RN, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/36/14921/contributors\">",
"     David E Wesson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/36/14921/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/36/14921/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/36/14921/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/36/14921/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/36/14921/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Firearm injury, a major cause of morbidity and mortality in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/1-3\">",
"     1-3",
"    </a>",
"    ], is an important medical and public health problem [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Children may be injured or killed in shootings, may lose parents, siblings, or other relatives in shootings, or may be adversely affected by witnessing shootings [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31097?source=see_link\">",
"     \"Childhood exposure to intimate partner violence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will describe the epidemiology of pediatric firearm injury, review strategies for prevention of firearm injuries in children, and define the clinician's role in firearm safety. The primary focus will be on unintentional handgun injuries. Intentional violence is discussed in detail separately. Societal issues associated with firearm injuries, such as Second Amendment rights and individual freedoms and responsibilities exceed the scope of this topic review. Some aspects of these issues are discussed in detail [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40617?source=see_link\">",
"     \"Peer violence and violence prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=see_link\">",
"     \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The word \"firearm\" is a general term that is used to describe all types of guns, including rifles, shotguns, and handguns [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/5\">",
"     5",
"    </a>",
"    ]. Traditional firearms propel a projectile by burning gunpowder. Nonpowder firearms such as pellet guns, air rifles, and BB guns use compressed air or carbon dioxide to propel the projectile [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/8\">",
"     8",
"    </a>",
"    ]. Although technically a firearm, a taser fires electrical probes to deliver a shock.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rifles and shotguns are long guns that typically are fired from the shoulder; rifles fire solid bullets, whereas shotguns fire shells that contain pellets.",
"     </li>",
"     <li>",
"      Handguns (eg, pistols and revolvers) are fired from the hand. Revolvers fire cartridges that are placed in one of several chambers within a revolving cylinder. Pistols fire ammunition from a magazine or clip; they can be manually operated or semi-automatic.",
"     </li>",
"     <li>",
"      Semi-automatic weapons reload automatically, but have a trigger that must be squeezed after each firing; ammunition usually is carried in magazines or clips of various capacities.",
"     </li>",
"     <li>",
"      Fully automatic weapons reload and fire continuously when the trigger is held and not released.",
"     </li>",
"     <li>",
"      Assault weapons are automatic or semi-automatic weapons that are capable of rapid fire from a large magazine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SCOPE OF THE PROBLEM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with other industrialized countries, the United States has the highest rate of firearm-related deaths among children younger than 15 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Firearm-related deaths among children have declined since 1993; however, in 2007, 2251 children younger than 19 years of age were killed by firearms, and in 2009, 9981 were injured (",
"    <a class=\"graphic graphic_table graphicRef50279 \" href=\"UTD.htm?35/16/36108\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/11\">",
"     11",
"    </a>",
"    ]. Most pediatric firearm-related deaths occur before [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/12,13\">",
"     12,13",
"    </a>",
"    ] or within 24 hours of hospital arrival [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although surveillance data for firearm injury are inadequate, and the intent potentially misclassified [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/15\">",
"     15",
"    </a>",
"    ], most firearm-related deaths are attributed to homicides affecting minority male teens [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Among individuals aged 1 to 18 years, homicide is the second leading cause of death, and firearms account for 68 percent of those homicides (",
"    <a class=\"graphic graphic_figure graphicRef64465 \" href=\"UTD.htm?39/46/40686\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/16\">",
"     16",
"    </a>",
"    ]. In unintentional fatalities, the overwhelming number of shooters (81 percent) was under the age of 25 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nearly all unintentional firearm fatalities in children occur in or around the home; 50 percent occur in the home of the victim, while nearly 40 percent occur in the home of a friend or relative [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Shootings in rural areas are more likely to occur outdoors and with a shotgun or rifle; shootings in urban areas are more likely to occur indoors and with a handgun [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/22\">",
"     22",
"    </a>",
"    ]. Unintentional shootings typically occur when children are unsupervised [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/20,23,24\">",
"     20,23,24",
"    </a>",
"    ] and out of school (eg, in the late afternoon, on weekends, and during the summer months and holiday seasons) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/19\">",
"     19",
"    </a>",
"    ]. Rural counties have higher rates of pediatric suicide associated with a firearm, while urban counties have significantly higher rates of pediatric homicides [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to the 2011 Youth Risk Behavior Survey, a nationwide survey of high school students, 5.1 percent of 9",
"    <sup>",
"     th",
"    </sup>",
"    - through 12",
"    <sup>",
"     th",
"    </sup>",
"    -grade students reported carrying a gun at least one day in the 30 days before the survey [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/26\">",
"     26",
"    </a>",
"    ]. Gun carrying was more common among boys than girls (8.6 versus 1.4percent). Gun carrying is associated with the use of violence and illicit drugs at school. Adolescents who carry guns to school report that they do so because they are afraid or because of peer pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Socioeconomic impact",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of firearm-related deaths and injuries to children extends beyond the pain and suffering of the victims and their families. Not only do firearm injuries put a burden on the health care and criminal justice systems, they also lead to a reduction in the work force due to deaths and disabilities. The total cost of firearm-related assaults, homicides, suicides, and self-inflicted firearm injuries in the United States in 2000 was estimated to exceed 33.5 billion dollars; cost estimates included direct medical costs (eg, ambulance, emergency department, medical examiner, etc) and lost productivity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hidden costs of firearm injuries are reflected in the fear and worry that permeate inner-city neighborhoods. A meta-analysis of 114 studies concluded that community violence, which included gun violence, was a predictor for the development of posttraumatic stress disorder (PTSD) in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/31\">",
"     31",
"    </a>",
"    ]. Because firearms can kill from a distance, the sounds of gunshots reduce the desirability of neighborhoods, thereby reducing urban property values, which results in lost revenue [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREVENTION OF FIREARM INJURIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification of strategies to prevent firearm injuries can be illustrated by using the Haddon Injury Control Model (",
"    <a class=\"graphic graphic_table graphicRef71200 \" href=\"UTD.htm?37/59/38843\">",
"     table 2",
"    </a>",
"    ). The Haddon Injury Control Model is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11767?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of pediatric injury prevention: Epidemiology; history; application\", section on 'Principles of injury prevention and control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most effective approach to injury prevention typically involves the combination of several strategies. Although counseling and education alone may not be particularly effective, they can be augmented by legislation and regulation (eg, for safer or childproof guns) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11767?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of pediatric injury prevention: Epidemiology; history; application\", section on 'Principles of injury prevention and control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pre-event strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the high potential for mortality in firearm injuries, pre-event strategies (ie, those that prevent the discharge of bullets) are the preferred methods of prevention. Pre-event strategies focus on changes in the following areas:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The behavior of the child or family",
"     </li>",
"     <li>",
"      The environment of the firearm",
"     </li>",
"     <li>",
"      The manufacture of firearms with safety features",
"     </li>",
"     <li>",
"      Educational, regulatory, and legislative changes",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Family counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that 2 to 13 percent of children younger than 18 years of age live in households that contain loaded firearms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/34-36\">",
"     34-36",
"    </a>",
"    ], and only 6 percent of families with children surveyed kept their guns unloaded, locked, locked up, or separate from ammunition [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/37\">",
"     37",
"    </a>",
"    ]. Families that keep firearms in the home often cite the need for personal protection. However, keeping guns in the home is associated with an increased risk of homicide by a family member or intimate acquaintance (odds ratio 2.7; 95% CI, 1.6-4.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Data from the 2006 National Violent Death Reporting System indicate that 73 percent of all unintentional firearm fatalities took place in a house or apartment, making these the most common places of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A case-control study was performed to measure the association of firearm storage practices and the risk of unintentional and self-inflicted firearm injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/40\">",
"     40",
"    </a>",
"    ]. Cases were events in which a child or adolescent (&lt;20 years) gained access to a firearm and shot him- or herself intentionally or unintentionally, or shot someone else unintentionally. Guns that were involved in such events (85 suicide attempts, 25 unintentional injuries) were less likely than were control guns:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      To have been stored unloaded (odds ratio [OR] 0.30)",
"     </li>",
"     <li>",
"      To have been locked away (OR 0.27)",
"     </li>",
"     <li>",
"      To have been separated from ammunition (OR 0.45)",
"     </li>",
"     <li>",
"      To have had the ammunition locked away (OR 0.39)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These four strategies, each associated with decreased risk of firearm injury, can be used to prevent suicide and unintentional injury in children and adolescents in gun-owning households.",
"   </p>",
"   <p>",
"    Parents may not realize the risk that a gun in the home poses to them or their children, may underestimate their child's ability to gain access to a gun, and may overestimate their child's ability to distinguish between a toy and real gun, to make good judgments about handling a gun, and to consistently follow rules about gun safety [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/41-46\">",
"     41-46",
"    </a>",
"    ]. In one telephone survey of households with children between 5 and 15 years of age, nearly 90 percent (regardless of gun ownership or age of child), responded that they believed that if their child found a gun, he or she would not touch it [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/47\">",
"     47",
"    </a>",
"    ]. Approximately one-half of respondents said their child was \"too smart\" or \"knew better\" than to handle a gun.",
"   </p>",
"   <p>",
"    Firearms may be easily accessible even if they are not kept in the home. In a national, random digit-dial survey, 7 percent of respondents reported they did not have a firearm in or around their home, but would be able to retrieve and fire one within 10 minutes if desired [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/48\">",
"     48",
"    </a>",
"    ]. Most guns that are involved in self-inflicted or unintentional injuries come from the home of the victim or the home of a friend or relative of the victim [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Access to firearms increases the risk of violence against peers. The majority of firearms used in school-based shootings in the United States were obtained from the homes of the perpetrators or their friends or relatives [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/50\">",
"     50",
"    </a>",
"    ]. Most of these weapons (89 percent) were handguns, and one-half were automatic or semiautomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/51\">",
"     51",
"    </a>",
"    ]. Access to firearms also increases the risk of completed suicide, particularly among adolescents. Surveillance data from the CDC recorded a high rate of fatalities from firearm related traumatic brain injuries among boys age 10 to 14 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/52\">",
"     52",
"    </a>",
"    ]. This finding suggests that other targeted prevention programs such as those identified by",
"    <a class=\"external\" href=\"file://www.colorado.edu/cspv/blueprints/\">",
"     Blueprints for Violence Prevention",
"    </a>",
"    may help reduce risk factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40617?source=see_link&amp;anchor=H7#H7\">",
"     \"Peer violence and violence prevention\", section on 'Access to firearms and weapon carrying'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=see_link&amp;anchor=H15#H15\">",
"     \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\", section on 'Firearms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given that guns in the home are associated with increased risks of homicide, completed suicide, and unintentional injury, the removal of guns from the home and the secured storage of guns in the home are logical strategies for reducing injury-related mortality. Many pediatric health care providers agree that physicians have a responsibility to counsel their patients and patients' families about firearm safety [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/53\">",
"     53",
"    </a>",
"    ]. More than 80 percent of pediatricians believe that such counseling helps to prevent firearm injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/54\">",
"     54",
"    </a>",
"    ]. However, fewer than 40 percent \"sometimes\" counsel families about the presence of guns in the home [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Reasons for the lack of counseling may include underestimation of gun ownership by their patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/56\">",
"     56",
"    </a>",
"    ], time constraints, and lack of perceived effectiveness of counseling [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Safety counseling by physicians has been shown to be effective in increasing seat belt and car seat use [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/59\">",
"     59",
"    </a>",
"    ]. Data supporting the efficacy of firearm safety counseling in preventing firearm injury are inconsistent. However, a meta-analysis of parenting interventions in the prevention of unintentional injuries suggests that safety counseling may improve the safe storage of firearms in the home [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 156 gun-owning family practice patients were assigned (by day) to receive brief verbal counseling, verbal counseling and a gun-safety brochure, or no counseling [",
"      <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/61\">",
"       61",
"      </a>",
"      ]. At the post-intervention interview, 58 to 64 percent of patients in the intervention groups made a safe change in gun storage practice (versus 33 percent in the control group).",
"     </li>",
"     <li>",
"      In another study, primary care physicians, nurse practitioners, and physicians' assistants were randomly assigned to provide a single, brief firearm-safety counseling session at a regularly scheduled health care visit, or to a control group that provided no such counseling. The counseling session included information about the risks of gun ownership and, for gun-owning families, recommendations regarding safe gun storage and discount coupons for gun storage devices [",
"      <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/62\">",
"       62",
"      </a>",
"      ]. The counseling session did not lead to changes in firearm ownership three months after the visit; however, the proportion of families that purchased trigger locks was greater among the intervention group (8 versus 2.5 percent, not statistically significant).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Providing a gun lock, rather than a discount coupon, to gun-owning families may increase the usage of gun locks. In another study, 82 participants received tailored counseling and a gun lock with instructions on how to use it [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/63\">",
"     63",
"    </a>",
"    ]. At follow-up, compared to baseline, there was an increase in the storage of guns in a locked compartment (77 versus 48 percent) and the use of gun locks (72 versus 0 percent), and a decrease in the storage of guns loaded and unlocked (7 versus 18 percent).",
"   </p>",
"   <p>",
"    Current evidence is insufficient to determine whether clinical advice influences patients to remove or safely store guns [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Nonetheless, as long as guns are present in the environments of children, health care providers are urged to inform parents of the risks of gun-related injuries and how such injuries can be prevented [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/4\">",
"     4",
"    </a>",
"    ]. Anticipatory guidance regarding guns is recommended by the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), the American College of Physicians, and the Society for Adolescent Medicine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/4,5,66,67\">",
"     4,5,66,67",
"    </a>",
"    ]. Physicians who counsel families about firearm safety may want to use the firearm safety tips provided by the",
"    <a class=\"external\" href=\"file://www.safekids.org/\">",
"     National Safe Kids Campaign",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef63269 \" href=\"UTD.htm?20/1/20507\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Clinician's role'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Gun safety programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gun safety programs focus on gun avoidance or the safe handling and storage of firearms. These programs usually are targeted to specific age groups. The",
"    <a class=\"external\" href=\"file://nrahq.org/safety/eddie/\">",
"     Eddie Eagle Gun Safety Program",
"    </a>",
"    , developed by the National Rifle Association (NRA), is probably the best-known gun safety program. It tells children that if they see a gun they should, \"Stop! Don't touch. Leave the area. Tell an adult.\" The NRA reports a 56 percent reduction in unintentional firearm injuries among children since 1988, the year the program was \"hatched\" [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/68\">",
"     68",
"    </a>",
"    ]. However, neither Eddie Eagle nor other gun safety programs have been systematically studied for efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Firearm mortality among children has declined since the early 1990s. However, the reasons for the decline are not clear. Possible explanations include prevention efforts, changes in factors that affect the frequency of violence, and changes in factors that affect whether guns are present when violence occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/70\">",
"     70",
"    </a>",
"    ]. The efficacy of gun safety programs that are directed at children should be evaluated before such programs are widely implemented [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gun safety programs alone do not appear to reduce the likelihood that children will handle firearms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/69\">",
"     69",
"    </a>",
"    ]. In one study, 70 children between the ages of four and seven years were randomly assigned to participate in a week-long firearm safety program or to the control group [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/42\">",
"     42",
"    </a>",
"    ]. After the program, pairs of children were observed in a structured setting in which they had access to a semiautomatic pistol. A total of 53 percent of the pairs played with the gun. Gun play behavior did not differ between the intervention and control groups.",
"   </p>",
"   <p>",
"    In another study, a convenience sample of 29 8- to 12-year-old boys and one or two of their siblings or playmates were placed in a room in which two water pistols and a handgun were concealed in separate drawers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/41\">",
"     41",
"    </a>",
"    ]. The pair or trio of boys was observed through a one-way mirror. Twenty-one of the groups (72 percent) discovered the handgun (approximately one-half of these boys thought that it was a toy or were unsure whether it was real); 16 groups handled it; and one or more of the boys in 10 of the groups pulled the trigger with enough force to discharge the firearm. More than 90 percent of the boys who handled the gun reported that they had received some sort of gun safety instruction in the past.",
"   </p>",
"   <p>",
"    Programs that describe the safe handling and storage of firearms are beyond the scope of this review but are provided by the",
"    <a class=\"external\" href=\"file://www.projectchildsafe.com/\">",
"     National Shooting Sports Foundation",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Gun safety features",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, counseling and gun safety programs are not particularly effective strategies for the prevention of firearm injuries. Strategies that prevent unintentional firing may be more effective, because children &mdash; even those who have received gun avoidance training&mdash; are likely to handle guns and pull the trigger [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Data from retrospective studies indicate that approximately one-third of unintentional shootings could be prevented if guns were required to have safety features to prevent unintentional firing [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the passage of gun regulations has been relatively unsuccessful, gun safety measures appear to have public support. In 1999, The National Opinion Research Center conducted a survey of a representative sample of 1200 Americans; 94 percent of the respondents favored federal handgun safety standards, and 88 percent agreed that all new handguns should be childproof [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Legislation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Gun modifications to protect children were initiated more than 100 years ago, when Smith and Wesson equipped a .38-caliber handgun with a safety device to prevent firing by children. Currently available safety devices to prevent the unintentional firing of handguns include [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Loaded chamber indicator",
"     </li>",
"     <li>",
"      Magazine disconnect device",
"     </li>",
"     <li>",
"      Grip safety device",
"     </li>",
"     <li>",
"      Firing pin block",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The loaded chamber indicator is a device that indicates the presence of a bullet in the chamber of a pistol. In one study, 13 percent of domestic pistols and 22 percent of imported pistols were equipped with a loaded chamber indicator [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magazine disconnect device prevents firing of a forgotten pistol cartridge. Even after the magazine has been removed from the pistol, a bullet may remain in the chamber. The magazine disconnect device physically prevents the gun from firing if the magazine or clip has been removed from the handle of a pistol. In one study, 21 percent of domestic and 22 percent of imported pistols were equipped with a magazine disconnect device [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A grip safety is a lever located on the grip of a handgun that must be compressed to permit firing. It was designed to make the gun difficult for a child to fire. In one study, 20 percent of domestic pistols, 6 percent of imported pistols, and no revolvers were equipped with a grip safety device [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The firing pin block, or drop safety, prevents discharge if the gun is unintentionally dropped on its hammer. In one study, 70 percent of domestic pistols, 87 percent of imported pistols, and 99 percent of revolvers were equipped with a drop safety device [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The manufacture of personalized handguns (ie, those that can be fired only by their owners) is a strategy that holds promise for the future [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Examples include a personal identification number that is programmed into the firearm at the time of sale, or the requirement of fingerprint recognition to fire the gun or remove it from the holster. The technology for the personalization of handguns has been developed for other applications and needs modification for use in firearms.",
"   </p>",
"   <p>",
"    In contrast to the potential development of safer handguns, efforts to develop \"safer bullets\" have been unsuccessful. Low-velocity rubber and plastic bullets have been used by the Israeli police for crowd control, but the use of these bullets has been associated with multiple fatalities. The resistance of the body surface at the site of impact determined whether a blunt or penetrating injury would result [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. Most of the fatalities resulted from ocular injuries penetrating into the brain. Injury severity also was increased by firing at close range.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Legislation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Legislative efforts to regulate handguns have been largely unsuccessful. Federal legislative efforts, such as the Childproof Handgun Act and the Firearm Safety and Violence Prevention Act, have all died in committee. Multiple attempts to bring handguns and ammunition under the jurisdiction of the Consumer Product Safety Commission (CPSC) have met with failure.",
"   </p>",
"   <p>",
"    Information about federal firearm regulations and current congressional firearm legislation efforts is available from the",
"    <a class=\"external\" href=\"file://www.csgv.org/issues-and-campaigns/federal-legislation\">",
"     Coalition to Stop Gun Violence",
"    </a>",
"    . Information about state firearm laws and ordinances is available through the",
"    <a class=\"external\" href=\"file://www.atf.gov/publications/download/p/atf-p-5300-5-2011/2009-30th-edition.pdf\">",
"     Bureau of Alcohol, tobacco, Firearms and Explosives",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In 1968, Congress passed the Gun Control Act, which, among other things, barred the importation of handguns that were not \"generally recognized as particularly suitable for or readily adaptable to sporting purposes\" [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/81\">",
"     81",
"    </a>",
"    ]. The Bureau of Alcohol, Tobacco, and Firearms (ATF) developed a set of design and performance specifications, known as the factoring criteria, to implement the \"sporting purposes\" test [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/82\">",
"     82",
"    </a>",
"    ]. Domestic manufacturers are exempt from the factoring criteria.",
"   </p>",
"   <p>",
"    Federal legislation that would extend the factoring criteria to all handguns sold in the United States, no matter where they were manufactured, has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/83-86\">",
"     83-86",
"    </a>",
"    ], but such legislation is unlikely to significantly increase the proportion of handguns with safety features [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/75\">",
"     75",
"    </a>",
"    ]. Two-thirds of domestically manufactured handguns already meet the factoring criteria, although fewer than 25 percent contain loaded chamber indicators, magazine disconnect devices, or grip safeties [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Legislation requiring safety features or limiting access to handguns may be a more effective means of preventing handgun injury. A 1976 law that banned the purchase, sale, transfer, or possession of handguns by civilians in Washington, DC was associated with a reduction in handgun-related homicide and suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/87\">",
"     87",
"    </a>",
"    ]. Handgun-related homicides declined by 3.3 per month, or 25 percent, and suicides by 0.6 per month, or 23 percent, compared to non-gun-related cases and rates in surrounding suburbs. In another study, crime rates in two similar cities were compared, one in the United States (Seattle) and the other in Canada (Vancouver), where availability of handguns is limited through more restrictive regulation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/88\">",
"     88",
"    </a>",
"    ]. During the study period, the risk of homicide by handgun was 4.8 times greater in Seattle than Vancouver; rates of homicide by other means were similar in the two cities. A systematic review of firearms laws and prevention of violence found insufficient evidence to determine the effectiveness of laws restricting firearm acquisition or banning access to specified firearms or ammunition [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some states, such as Massachusetts and California, have passed regulations that require a safety feature to prevent firing by children for all commercially sold handguns. Other states have laws that make gun owners criminally liable if someone is injured because a child gains unsupervised access to a gun. In an ecological study of firearm mortality from 1979 to 1994, among states with such laws, unintentional shooting deaths among children younger than 15 years were reduced by 23 percent (95% CI 6-37 percent) during the years covered by the laws [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/90\">",
"     90",
"    </a>",
"    ]. A systematic review of firearms laws and prevention of violence found insufficient evidence to determine the effectiveness of child access prevention laws [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/89\">",
"     89",
"    </a>",
"    ]. However, comparison of suicide rates among adolescents (14 to 20 years) from states with and without various types of firearm legislation found a modest decrease (8.3 percent) in suicide rates among 14- to 17-year old children in the states with child access prevention laws (5.97 per 100,000 population versus the projected 6.51 per 100,000 population) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several local municipalities and individuals have brought suit against gun manufacturers for safety design failures. Because many of these cases are settled before the case is brought to trial, it is not clear whether this approach will influence gun manufacturers to design guns with safety features to reduce the incidence of gun-related injuries to children. The continued use of this strategy may be limited by legislation proposed in Congress to shield gun manufacturers from civil claims made by victims of gun violence [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Event strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Event strategies are designed to modulate the transfer of energy from the agent (ie, bullet) to the child. One such strategy is to minimize the discharging of firearms in the environments of children (eg, limit firearm practice to practice ranges). Few strategies are available once the bullet is discharged from the gun. The use of bulletproof vests has been effective for police officers and military personnel, but is impractical for children.",
"   </p>",
"   <p>",
"    The logical, but unproven, premise that the discharge of fewer bullets would result in decreased morbidity and mortality was the basis for legislation to limit the availability of assault weapons (automatic or semiautomatic firearms). The Violent Crime Control and Law Enforcement Act of 1994 prohibited the manufacture, transfer, and possession of semiautomatic assault weapons and ammunition magazines that hold more than 10 rounds of ammunition (except for law enforcement officials). The law expired in September 2004.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Post-event strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-event strategies are designed to prevent morbidity and mortality in the injured child (the classic medical response model). Ongoing efforts to improve the children's emergency medical system and rehabilitation are always recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26553?source=see_link\">",
"     \"Prehospital pediatrics and emergency medical services (EMS)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surveillance for and analysis of data from firearm injuries can help to identify risk factors, causes, and possible prevention strategies for the future [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. Full, accurate documentation of injury events, including the \"who, what, when, where, why, and how\" of the injury occurrence and whether protective equipment (eg, a safety device) was used, is an essential step in injury prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/95\">",
"     95",
"    </a>",
"    ]. This information helps to define the extent of the problem and provides the basis for preventive counseling and prevention strategies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLINICIAN'S ROLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Firearm-related injuries are an important cause of death among children and adolescents. Pediatric health professionals can provide leadership for improved gun safety through education of patients and families, advocacy for legislation that protects children from firearm injuries, or becoming informed spokespersons for firearm safety.",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics (AAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/4\">",
"     4",
"    </a>",
"    ], the American Academy of Family Physicians (AAFP) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/66\">",
"     66",
"    </a>",
"    ], the Society for Adolescent Medicine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/67\">",
"     67",
"    </a>",
"    ], and the American College of Physicians (ACP) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/5\">",
"     5",
"    </a>",
"    ] have issued policy or position statements regarding the prevention of firearm injuries.",
"   </p>",
"   <p>",
"    The following recommendations are included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The absence of guns from the home is the most effective means of prevention of firearm injuries in children.",
"     </li>",
"     <li>",
"      Health care providers are encouraged to inform their patients and patients' parents about the dangers of firearms. Parents who possess guns, particularly handguns, should be encouraged to remove them from the home or to store them safely (unloaded and locked, with ammunition stored securely in a separate location).",
"     </li>",
"     <li>",
"      Guns should be regulated like other consumer products (eg, by the Consumer Product Safety Commission [CPSC]).",
"     </li>",
"     <li>",
"      The above groups support legislation restricting the possession and sale of firearms (particularly assault weapons), requiring operative trigger locks, and requiring the safe storage of firearms (ie, locked away and unloaded).",
"     </li>",
"     <li>",
"      Firearm injury prevention and intervention strategies and regulations should be evaluated for effectiveness (eg, safe storage techniques and educational programs) to better allocate resources and prevent the perpetuation of ineffective strategies.",
"     </li>",
"     <li>",
"      A national firearm injury surveillance data system should be developed and maintained [",
"      <a class=\"abstract\" href=\"UTD.htm?14/36/14921/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following resources may be helpful to pediatric health care providers in counseling their patients and patients' families about firearm safety:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.aafp.org/online/en/home.html\">",
"       American Academy of Family Physicians",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.aap.org\">",
"       American Academy of Pediatrics",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.bradycenter.org/\">",
"       Brady Center to Prevent Gun Violence",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.csgv.org/\">",
"       The Coalition to Stop Gun Violence",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.kidsandguns.com/\">",
"       Common Sense about Kids and Guns",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.jhsph.edu/gunpolicy\">",
"       Johns Hopkins Center for Gun Policy Research",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.safekids.org/\">",
"       National Safe Kids Campaign",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22889628\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Firearm injuries and deaths among children are common in the United States. Most unintentional firearm deaths occur in or around the home. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Scope of the problem'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Strategies to prevent firearm injuries in children can be categorized according to their time of implementation: pre-event, event, or post-event (",
"      <a class=\"graphic graphic_table graphicRef71200 \" href=\"UTD.htm?37/59/38843\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Prevention of firearm injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Policy and position statements from the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), the Society for Adolescent Medicine, and the American College of Physicians (ACP) encourage healthcare providers to inform their patients and patients' parents about the dangers of firearms.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/1\">",
"      Christoffel KK, Christoffel T. Handguns as a pediatric problem. Pediatr Emerg Care 1986; 2:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/2\">",
"      Coben JH, Steiner CA. Hospitalization for firearm-related injuries in the United States, 1997. Am J Prev Med 2003; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/3\">",
"      Zavoski RW, Lapidus GD, Lerer TJ, Banco LI. A population-based study of severe firearm injury among children and youth. Pediatrics 1995; 96:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/4\">",
"      Dowd MD, Sege RD, Council on Injury, Violence, and Poison Prevention Executive Committee, American Academy of Pediatrics. Firearm-related injuries affecting the pediatric population. Pediatrics 2012; 130:e1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/5\">",
"      Firearm injury prevention. American College of Physicians. Ann Intern Med 1998; 128:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/6\">",
"      Garbarino J, Bradshaw CP, Vorrasi JA. Mitigating the effects of gun violence on children and youth. Future Child 2002; 12:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/7\">",
"      Rawson B. Aiming for prevention: medical and public health approaches to small arms, gun violence, and injury. Croat Med J 2002; 43:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/8\">",
"      O'Neill PJ, Lumpkin MF, Clapp B, et al. Significant pediatric morbidity and mortality from intracranial ballistic injuries caused by nonpowder gunshot wounds. A case series. Pediatr Neurosurg 2009; 45:205.",
"     </a>",
"    </li>",
"    <li>",
"     Fingerhut LA, Warner M. Injury Chartbook. In: Health, United States, 1196-97, National Center for Health Statistics, Hyattsville, MD 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/10\">",
"      Richardson EG, Hemenway D. Homicide, suicide, and unintentional firearm fatality: comparing the United States with other high-income countries, 2003. J Trauma 2011; 70:238.",
"     </a>",
"    </li>",
"    <li>",
"     Web-based Injury Statistics Query and Reporting System. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. www.cdc.gov/ncipc/wisqars (Accessed on May 14, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/12\">",
"      Cooper A, Barlow B, Davidson L, et al. Epidemiology of pediatric trauma: importance of population-based statistics. J Pediatr Surg 1992; 27:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/13\">",
"      Lee RK, Waxweiler RJ, Dobbins JG, Paschetag T. Incidence rates of firearm injuries in Galveston, Texas, 1979-1981. Am J Epidemiol 1991; 134:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/14\">",
"      Nance ML, Branas CC, Stafford PW, et al. Nonintracranial fatal firearm injuries in children: implications for treatment. J Trauma 2003; 55:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/15\">",
"      Schaechter J, Duran I, De Marchena J, et al. Are \"accidental\" gun deaths as rare as they seem? A comparison of medical examiner manner of death coding with an intent-based classification approach. Pediatrics 2003; 111:741.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Injury prevention and control: Data and statistics (WISQARS). file://www.cdc.gov/injury/wisqars/index.html (Accessed on August 09, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/17\">",
"      Senger C, Keijzer R, Smith G, Muensterer OJ. Pediatric firearm injuries: a 10-year single-center experience of 194 patients. J Pediatr Surg 2011; 46:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/18\">",
"      Hemenway D, Barber C, Miller M. Unintentional firearm deaths: a comparison of other-inflicted and self-inflicted shootings. Accid Anal Prev 2010; 42:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/19\">",
"      Li G, Baker SP, DiScala C, et al. Factors associated with the intent of firearm-related injuries in pediatric trauma patients. Arch Pediatr Adolesc Med 1996; 150:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/20\">",
"      Wintemute GJ, Teret SP, Kraus JF, et al. When children shoot children. 88 unintended deaths in California. JAMA 1987; 257:3107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/21\">",
"      Karch DL, Dahlberg LL, Patel N, et al. Surveillance for violent deaths--national violent death reporting system, 16 States, 2006. MMWR Surveill Summ 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     National Safe Kids Campaign (NSKC). Unintentional Firearm Injury Fact Sheet. NSKC, Washington, DC, 2004.",
"    </li>",
"    <li>",
"     Smith DR, Cohen J, Lautman B. Child's play: A study of 266 unintentional handgun shootings of children. Center to Prevent Handgun Violence, Washington DC, 1992.",
"    </li>",
"    <li>",
"     Center to Prevent Handgun Violence. The killing seasons: A study of when unintentional handgun shootings among children occur. Center to Prevent Handgun Violence, Washington, DC 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/25\">",
"      Nance ML, Carr BG, Kallan MJ, et al. Variation in pediatric and adolescent firearm mortality rates in rural and urban US counties. Pediatrics 2010; 125:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/26\">",
"      Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance - United States, 2011. MMWR Surveill Summ 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/27\">",
"      McNabb SJ, Farley TA, Powell KE, et al. Correlates of gun-carrying among adolescents in south Louisiana. Am J Prev Med 1996; 12:96.",
"     </a>",
"    </li>",
"    <li>",
"     In the Line of Fire: Youth, Guns, and Violence in Urban America, Aldine Transaction, New York 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/29\">",
"      Blumstein A, Cork D. Linking gun availability to youth gun violence. Law Contemp Prob 1996; 59:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/30\">",
"      Corso PS, Mercy JA, Simon TR, et al. Medical costs and productivity losses due to interpersonal and self-directed violence in the United States. Am J Prev Med 2007; 32:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/31\">",
"      Fowler PJ, Tompsett CJ, Braciszewski JM, et al. Community violence: a meta-analysis on the effect of exposure and mental health outcomes of children and adolescents. Dev Psychopathol 2009; 21:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/32\">",
"      Cullen JB, Levitt SD. Crime, urban flight, and the consequences for cities. Rev Econom Stat 1999; 81:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/33\">",
"      Christoffel KK. Toward reducing pediatric injuries from firearms: charting a legislative and regulatory course. Pediatrics 1991; 88:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/34\">",
"      Powell KE, Jacklin BC, Nelson DE, Bland S. State estimates of household exposure to firearms, loaded firearms, and handguns, 1991 through 1995. Am J Public Health 1998; 88:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/35\">",
"      Schuster MA, Franke TM, Bastian AM, et al. Firearm storage patterns in US homes with children. Am J Public Health 2000; 90:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/36\">",
"      Johnson RM, Miller M, Vriniotis M, et al. Are household firearms stored less safely in homes with adolescents?: Analysis of a national random sample of parents. Arch Pediatr Adolesc Med 2006; 160:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/37\">",
"      Connor SM. The association between presence of children in the home and firearm-ownership and -storage practices. Pediatrics 2005; 115:e38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/38\">",
"      Kellermann AL, Rivara FP, Rushforth NB, et al. Gun ownership as a risk factor for homicide in the home. N Engl J Med 1993; 329:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/39\">",
"      Cummings P, Koepsell TD. Does owning a firearm increase or decrease the risk of death? JAMA 1998; 280:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/40\">",
"      Grossman DC, Mueller BA, Riedy C, et al. Gun storage practices and risk of youth suicide and unintentional firearm injuries. JAMA 2005; 293:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/41\">",
"      Jackman GA, Farah MM, Kellermann AL, Simon HK. Seeing is believing: what do boys do when they find a real gun? Pediatrics 2001; 107:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/42\">",
"      Hardy MS. Teaching firearm safety to children: failure of a program. J Dev Behav Pediatr 2002; 23:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/43\">",
"      Laraque D, Spivak H, Bull M. Serious firearm injury prevention does make sense. Pediatrics 2001; 107:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/44\">",
"      Azrael D, Miller M, Hemenway D. Are household firearms stored safely? It depends on whom you ask. Pediatrics 2000; 106:E31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/45\">",
"      Farah MM, Simon HK, Kellermann AL. Firearms in the home: parental perceptions. Pediatrics 1999; 104:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/46\">",
"      Stennies G, Ikeda R, Leadbetter S, et al. Firearm storage practices and children in the home, United States, 1994. Arch Pediatr Adolesc Med 1999; 153:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/47\">",
"      Connor SM, Wesolowski KL. \"They're too smart for that\": predicting what children would do in the presence of guns. Pediatrics 2003; 111:E109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/48\">",
"      Ikeda RM, Dahlberg LL, Kresnow MJ, et al. Studying \"exposure\" to firearms: household ownership v access. Inj Prev 2003; 9:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/49\">",
"      Grossman DC, Reay DT, Baker SA. Self-inflicted and unintentional firearm injuries among children and adolescents: the source of the firearm. Arch Pediatr Adolesc Med 1999; 153:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/50\">",
"      Centers for Disease Control and Prevention (CDC). Source of firearms used by students in school-associated violent deaths--United States, 1992-1999. MMWR Morb Mortal Wkly Rep 2003; 52:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/51\">",
"      Kachur SP, Stennies GM, Powell KE, et al. School-associated violent deaths in the United States, 1992 to 1994. JAMA 1996; 275:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/52\">",
"      Coronado VG, Xu L, Basavaraju SV, et al. Surveillance for traumatic brain injury-related deaths--United States, 1997-2007. MMWR Surveill Summ 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/53\">",
"      Grossman DC, Mang K, Rivara FP. Firearm injury prevention counseling by pediatricians and family physicians. Practices and beliefs. Arch Pediatr Adolesc Med 1995; 149:973.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics, Division of Health Policy Research. Periodic Survey of Fellows, Executive Summary. Periodic Survey #47: Firearm Safety Counseling. www.aap.org/research/periodicsurvey/ps47exs.htm (Accessed on April 20, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/55\">",
"      Barkin S, Duan N, Fink A, et al. The smoking gun: do clinicians follow guidelines on firearm safety counseling? Arch Pediatr Adolesc Med 1998; 152:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/56\">",
"      Becher EC, Christakis NA. Firearm injury prevention counseling: are We missing the mark? Pediatrics 1999; 104:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/57\">",
"      Cheng TL, DeWitt TG, Savageau JA, O'Connor KG. Determinants of counseling in primary care pediatric practice: physician attitudes about time, money, and health issues. Arch Pediatr Adolesc Med 1999; 153:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/58\">",
"      Cohen LR, Runyan CW, Downs SM, Bowling JM. Pediatric injury prevention counseling priorities. Pediatrics 1997; 99:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/59\">",
"      Bass JL, Christoffel KK, Widome M, et al. Childhood injury prevention counseling in primary care settings: a critical review of the literature. Pediatrics 1993; 92:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/60\">",
"      Kendrick D, Barlow J, Hampshire A, et al. Parenting interventions and the prevention of unintentional injuries in childhood: systematic review and meta-analysis. Child Care Health Dev 2008; 34:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/61\">",
"      Albright TL, Burge SK. Improving firearm storage habits: impact of brief office counseling by family physicians. J Am Board Fam Pract 2003; 16:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/62\">",
"      Grossman DC, Cummings P, Koepsell TD, et al. Firearm safety counseling in primary care pediatrics: a randomized, controlled trial. Pediatrics 2000; 106:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/63\">",
"      Coyne-Beasley T, Schoenbach VJ, Johnson RM. \"Love our kids, lock your guns\": a community-based firearm safety counseling and gun lock distribution program. Arch Pediatr Adolesc Med 2001; 155:659.",
"     </a>",
"    </li>",
"    <li>",
"     Preventing youth violence. In: US Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd ed, Williams &amp; Wilkins, Baltimore 1996. p.687.",
"    </li>",
"    <li>",
"     DiGuiseppi C. Counseling to preven household and recreational injuries. In: US Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd ed, DiGuiseppi C, Atkins D, Woolf SH (Eds), Williams &amp; Wilkins, Baltimore 1996. p.689.",
"    </li>",
"    <li>",
"     American Academy of Family Physicians. Firearm Safety. file://www.aafp.org/online/en/home/policy/policies/f/firearmsafety.html (Accessed on October 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/67\">",
"      Duke N, Resnick MD, Borowsky IW. Adolescent firearm violence: position paper of the Society for Adolescent Medicine. J Adolesc Health 2005; 37:171.",
"     </a>",
"    </li>",
"    <li>",
"     National Rifle Association. Eddie Eagle Web site. www.nrahq.org/safety/eddie/awards.asp (Accessed on April 20, 2006).",
"    </li>",
"    <li>",
"     Promising strategies to reduce gun violence. United States Department of Justice. Office of Justice Programs. Office of Juvenile Justice and Delinquency Programs. file://www.ojjdp.gov/pubs/gun_violence/173950.pdf (Accessed on August 09, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/70\">",
"      Fingerhut LA, Christoffel KK. Firearm-related death and injury among children and adolescents. Future Child 2002; 12:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/71\">",
"      American Academy of Pediatrics Committee on Injury and Poison Prevention: Firearm injuries affecting the pediatric population. Pediatrics 1992; 89:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/72\">",
"      Ismach RB, Reza A, Ary R, et al. Unintended shootings in a large metropolitan area: an incident-based analysis. Ann Emerg Med 2003; 41:10.",
"     </a>",
"    </li>",
"    <li>",
"     United States General Accounting Office. Accidental shootings: Many deaths and injuries caused by firearms could be prevented. US General Accounting Office; Washington, DC, 1991.",
"    </li>",
"    <li>",
"     Smith TW. 2001 National Gun Policy Survey of the National Opinion Research Center: Research findings. National Opinion Research Center, Chicago, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/75\">",
"      Milne JS, Hargarten SW, Kellermann AL, Wintemute GJ. Effect of current federal regulations on handgun safety features. Ann Emerg Med 2003; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/76\">",
"      Vernick JS, Meisel ZF, Teret SP, et al. \"I didn't know the gun was loaded\": an examination of two safety devices that can reduce the risk of unintentional firearm injuries. J Public Health Policy 1999; 20:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/77\">",
"      Teret SP, Lewin NL. Policy and technology for safer guns: an update. Ann Emerg Med 2003; 41:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/78\">",
"      Teret SP, Culross PL. Product-oriented approaches to reducing youth gun violence. Future Child 2002; 12:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/79\">",
"      Mahajna A, Aboud N, Harbaji I, et al. Blunt and penetrating injuries caused by rubber bullets during the Israeli-Arab conflict in October, 2000: a retrospective study. Lancet 2002; 359:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/80\">",
"      Hiss J, Hellman FN, Kahana T. Rubber and plastic ammunition lethal injuries: the Israeli experience. Med Sci Law 1997; 37:139.",
"     </a>",
"    </li>",
"    <li>",
"     The Gun Control Act of 1968. Pub Law No. 90-618, 82 Stat 1213.",
"    </li>",
"    <li>",
"     Department of the Treasury, Bureau of Alcohol, Tobacco, and Firearms. Factoring Criteria for Weapons. Form 4590 (5330.5)., Bureau of Alcohol, Tobacco, and Firearms, Washington, DC, 1983.",
"    </li>",
"    <li>",
"     American Handgun Standards Act of 1997. S70, 105th Cong, (1997-1998).",
"    </li>",
"    <li>",
"     American Handgun Standards Act of 1997. HR492, 105th Cong, (1997-1998).",
"    </li>",
"    <li>",
"     American Handgun Standards Act of 1999. S193, 106th Cong, (1999-2000).",
"    </li>",
"    <li>",
"     To Prohibit the Possession or Transfer of Junk Guns, Also Known as Saturday Night Specials. HR35, 106th.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/87\">",
"      Loftin C, McDowall D, Wiersema B, Cottey TJ. Effects of restrictive licensing of handguns on homicide and suicide in the District of Columbia. N Engl J Med 1991; 325:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/88\">",
"      Sloan JH, Kellermann AL, Reay DT, et al. Handgun regulations, crime, assaults, and homicide. A tale of two cities. N Engl J Med 1988; 319:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/89\">",
"      Hahn RA, Bilukha OO, Crosby A, et al. First reports evaluating the effectiveness of strategies for preventing violence: early childhood home visitation. Findings from the Task Force on Community Preventive Services. MMWR Recomm Rep 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/90\">",
"      Cummings P, Grossman DC, Rivara FP, Koepsell TD. State gun safe storage laws and child mortality due to firearms. JAMA 1997; 278:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/91\">",
"      Webster DW, Vernick JS, Zeoli AM, Manganello JA. Association between youth-focused firearm laws and youth suicides. JAMA 2004; 292:594.",
"     </a>",
"    </li>",
"    <li>",
"     VandeHei J. Gun Firms on Verge of Winning New Shield. The Washington Post, May 5, 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/93\">",
"      Rosenberg ML, Hammond WR. Surveillance the key to firearm injury prevention. Am J Prev Med 1998; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/94\">",
"      Frattaroli S, Teret SP. Why firearm injury surveillance? Am J Prev Med 1998; 15:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14921/abstract/95\">",
"      Katcher ML, Agran P, Laraque D, et al. The hospital record of the injured child and the need for external cause-of-injury codes. American Academy of Pediatrics. Committee on Injury and Poison Prevention, 1998-1999. Pediatrics 1999; 103:524.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2848 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-190.92.87.104-BD5B12EED9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_36_14921=[""].join("\n");
var outline_f14_36_14921=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22889628\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SCOPE OF THE PROBLEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Socioeconomic impact",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREVENTION OF FIREARM INJURIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pre-event strategies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Family counseling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Gun safety programs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Gun safety features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Legislation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Event strategies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Post-event strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLINICIAN'S ROLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22889628\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2848\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2848|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/46/40686\" title=\"figure 1\">",
"      Homicides in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2848|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/16/36108\" title=\"table 1\">",
"      Firearm injuries and deaths",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/59/38843\" title=\"table 2\">",
"      Haddon model firearm injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/1/20507\" title=\"table 3\">",
"      Firearm safety tips",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31097?source=related_link\">",
"      Childhood exposure to intimate partner violence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11767?source=related_link\">",
"      Overview of pediatric injury prevention: Epidemiology; history; application",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40617?source=related_link\">",
"      Peer violence and violence prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26553?source=related_link\">",
"      Prehospital pediatrics and emergency medical services (EMS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=related_link\">",
"      Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_36_14922="Linear IgA bullous dermatosis";
var content_f14_36_14922=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Linear IgA bullous dermatosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/36/14922/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/36/14922/contributors\">",
"     Russell P Hall, III, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/36/14922/contributors\">",
"     Caroline L Rao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/36/14922/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/36/14922/contributors\">",
"     John J Zone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/36/14922/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/36/14922/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/36/14922/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H28759724\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Linear IgA bullous dermatosis (LABD), also known as linear IgA disease, is a rare, idiopathic or drug-induced autoimmune blistering disease characterized by the linear deposition of IgA at the dermoepidermal junction. Although the clinical features of this disorder can be difficult to distinguish from dermatitis herpetiformis (another autoimmune blistering disease), the distinct immunopathologic findings in LABD and the absence of an associated gluten-sensitive enteropathy confirm the status of LABD as a distinct disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LABD occurs in both adults and children, and since the late 1980s, the disorder designated as chronic bullous disease of childhood has been recognized as the childhood form of LABD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/2\">",
"     2",
"    </a>",
"    ]. Children classically present with widespread annular blisters that exhibit a predilection for the lower abdomen, thighs, and groin. In adults, annular lesions are less common and the extensor extremities, face, and trunk are frequently affected. Mucosal lesions, manifesting as inflammation, erosions, or scarring, may also occur in patients with LABD.",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and management of LABD in adults and children will be reviewed here. A general approach to the evaluation of patients with blistering skin lesions is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14186?source=see_link\">",
"     \"Approach to the patient with cutaneous blisters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28759731\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;LABD is a rare disorder. Reports of disease incidence from various countries have ranged from less than 0.5 to 2.3 cases per million individuals per year [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/3\">",
"     3",
"    </a>",
"    ]. A predilection for LABD based upon ethnicity or sex has not been definitively established [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adults frequently develop LABD in the later stages of life, with many cases occurring after the age of 60 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In children, the disease usually presents between the ages of 6 months and 10 years; in a series of 25 affected children, the average age of onset was 4.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/2\">",
"     2",
"    </a>",
"    ]. Rarely, neonates are affected [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H827478\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the presence of IgA antibodies bound to the basement membrane zone is accepted as a characteristic feature of LABD, the mechanism of lesion formation in this disorder is not well understood. Both humoral and cellular immune responses may be involved in the pathogenesis of this disease. In particular, tissue injury resulting from an antibody-induced local inflammatory response and the release of proteolytic enzymes by neutrophils and other inflammatory cells may contribute to the development of skin and mucosal lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with LABD have IgA1 antibodies that target a 97 kDa antigen and a 120 kDa antigen within the basement membrane zone. Both of these antigens are fragments of the extracellular portion of bullous pemphigoid antigen 2 (BP180), a transmembrane protein that plays a key role in epidermal-dermal adhesion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Less frequently, the NC16a epitope on BP180 has been associated with LABD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    In addition, the presence of both IgA and IgG antibodies against basement membrane zone components has been detected in a subset of patients with features consistent with LABD. A Japanese review of 213 reported cases found that such findings were present in approximately 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/11\">",
"     11",
"    </a>",
"    ]. Additional study is necessary to determine whether this presentation represents a distinct disorder or a variant of LABD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1919394\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients with LABD, the inciting factor for the disease is unknown.",
"   </p>",
"   <p>",
"    Although multiple case reports have documented drug exposure as a precipitating factor [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/12\">",
"     12",
"    </a>",
"    ], formal studies validating the existence of drug-induced LABD are lacking.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    is the pharmacologic agent most frequently reported as a potential inciting factor [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/12\">",
"     12",
"    </a>",
"    ]. Examples of other drugs that may be linked to LABD include a variety of antibiotics, nonsteroidal antiinflammatory agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/25/9625?source=see_link\">",
"     piroxicam",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    , interferon alpha, and somatostatin (",
"    <a class=\"graphic graphic_table graphicRef83569 \" href=\"UTD.htm?7/26/7596\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/3,13-15\">",
"     3,13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic factors also may contribute to the development of LABD. Associations of LABD with human leukocyte antigen (HLA) B8, HLA Cw7, HLA DR3, HLA DQ2, and the tumor necrosis factor-2 allele have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/16\">",
"     16",
"    </a>",
"    ]. Further study is necessary to determine the role of both drugs and genetics in LABD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28759738\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;LABD may present with lesions on the skin, on the mucous membranes, or in both locations. Although both children and adults develop LABD, differences in the clinical characteristics of the disease are observed among these populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H829252\">",
"    <span class=\"h2\">",
"     Cutaneous lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since blister formation in LABD occurs subepidermally, the vesicles and bullae that form on the skin of affected patients typically have a tense, rather than flaccid, pemphigus-like quality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14186?source=see_link&amp;anchor=H5172250#H5172250\">",
"     \"Approach to the patient with cutaneous blisters\", section on 'Blister quality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A summary of the clinical characteristics of adult and childhood LABD is provided below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Children",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      LABD of childhood, also known as chronic bullous disease of childhood, most often presents with the acute development of vesicles or bullae on sites of inflamed or noninflamed skin (",
"      <a class=\"graphic graphic_picture graphicRef50728 graphicRef52805 graphicRef74317 graphicRef62298 \" href=\"UTD.htm?39/30/40426\">",
"       picture 1A-D",
"      </a>",
"      ). New blisters often form at the periphery of resolving lesions, resulting in an arciform or annular appearance (",
"      <a class=\"graphic graphic_picture graphicRef56434 \" href=\"UTD.htm?15/62/16359\">",
"       picture 2E",
"      </a>",
"      ). Such lesions are frequently described as resembling strings of pearls, crowns of jewels, or rosettes [",
"      <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/17\">",
"       17",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The distribution of skin lesions usually is widespread, involving the trunk, face (particularly perioral area), genitalia, hands, feet, and other sites. The most intensely involved areas are often the perineum, lower abdomen, and inner thighs [",
"      <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/2,4,18\">",
"       2,4,18",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Affected children may be asymptomatic, but pruritus is common and may be severe. In some patients, intense pruritus heralds recurrences of the disease [",
"      <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Adults",
"      </strong>",
"      &ndash; Adult patients with LABD typically experience an abrupt onset of skin lesions; less frequently, the disease develops more slowly [",
"      <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/19\">",
"       19",
"      </a>",
"      ]. The tense vesicles and bullae may arise on normal skin or within inflammatory plaques (",
"      <a class=\"graphic graphic_picture graphicRef80884 graphicRef59901 graphicRef71725 graphicRef51248 graphicRef56434 \" href=\"UTD.htm?42/55/43898\">",
"       picture 2A-E",
"      </a>",
"      ). Annular lesions demonstrating peripheral vesiculation develop less frequently in adults than in children [",
"      <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/19\">",
"       19",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The trunk, extensor extremities, buttocks, and face (particularly the perioral area) are common sites for lesion development [",
"      <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/3\">",
"       3",
"      </a>",
"      ]. This distribution can make it difficult to distinguish LABD from dermatitis herpetiformis, which affects similar sites. Localized variants of LABD presenting as limited blistering eruptions or annular inflammatory plaques have also been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/20-26\">",
"       20-26",
"      </a>",
"      ]. Pruritus may be intense, and can result in the development of excoriated papules or prurigo nodularis-like lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28759745\">",
"    <span class=\"h2\">",
"     Mucosal involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucous membrane involvement can occur in both adults and children. Mucosal disease occurs in up to 80 percent of adult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/2\">",
"     2",
"    </a>",
"    ]. Estimates of the incidence of mucosal LABD in childhood disease vary widely. In a series of 25 children with LABD in the United Kingdom, mucosal involvement was present in 64 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/2\">",
"     2",
"    </a>",
"    ]. In contrast, similarly sized Japanese and Tunisian retrospective studies found mucosal disease in only 3 and 8 percent of children, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/11,29\">",
"     11,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mucosal lesions primarily present as erosions or ulcers; the detection of intact vesicles or bullae is uncommon. Any mucosal surface may be affected, including the oral cavity, conjunctiva, nose, genitalia, pharynx, larynx, anus, and esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/2,3,5,19\">",
"     2,3,5,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The oral and ocular mucosa are the most commonly affected mucosal sites [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In patients with oral disease, lesions are frequently located on the palate, palatine arches, or buccal mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/3\">",
"     3",
"    </a>",
"    ]. Erosive gingivitis and erosive cheilitis may also occur as manifestations of oral LABD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/2,30,31\">",
"     2,30,31",
"    </a>",
"    ]. Ocular disease may present with conjunctival redness, ocular discharge, ocular pain, or a foreign-body sensation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mucosal scarring may occur, and similar to patients with ocular cicatricial pemphigoid, patients with ocular LABD can develop symblepharon and ectropion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/2/4138?source=see_link\">",
"     \"Ocular cicatricial pemphigoid\"",
"    </a>",
"    .) Examples of serious adverse consequences of cicatrizing mucosal disease include corneal damage leading to blindness, airway obstruction, and esophageal strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely, the mucosa is the initial or only site of LABD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/30,35-37\">",
"     30,35-37",
"    </a>",
"    ]. Mucosal-predominant LABD is considered a form of mucous membrane pemphigoid [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15273?source=see_link&amp;anchor=H589237#H589237\">",
"     \"Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28759752\">",
"    <span class=\"h2\">",
"     Drug-induced linear IgA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical findings in drug-induced LABD usually do not differ significantly from those of idiopathic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/12\">",
"     12",
"    </a>",
"    ]. Rarely, lesions are localized rather than widespread or resemble morbilliform drug eruptions, erythema multiforme, or toxic epidermolytic necrolysis (",
"    <a class=\"graphic graphic_picture graphicRef64559 \" href=\"UTD.htm?41/52/42823\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/39-44\">",
"     39-44",
"    </a>",
"    ]. The presence of mucosal involvement varies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most reported cases of drug-induced LABD have occurred in adults, but LABD in association with drug exposure has also been observed in children [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/2,12,13\">",
"     2,12,13",
"    </a>",
"    ]. The disease usually begins within one month of drug initiation, and often resolves within several weeks following drug cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/13,45,46\">",
"     13,45,46",
"    </a>",
"    ]. However, the eruption persists for longer in some patients. In addition, reexposure to an inciting agent can result in the rapid recurrence of blistering [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28759759\">",
"    <span class=\"h1\">",
"     ASSOCIATED DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;LABD has occurred in the setting of ulcerative colitis, hematologic or solid organ malignancies, and other disorders.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Ulcerative colitis",
"      </strong>",
"      &ndash; Ulcerative colitis is the most common benign disorder reported in association with LABD [",
"      <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/11,48-52\">",
"       11,48-52",
"      </a>",
"      ]. In a retrospective study of 70 patients with LABD referred to two dermatology departments in the United Kingdom, five patients (7 percent) had LABD, and ulcerative colitis preceded the diagnosis of LABD by an average of six years [",
"      <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/49\">",
"       49",
"      </a>",
"      ]. Moreover, a Japanese review of 213 reported cases of LABD identified four patients with this disease [",
"      <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/11\">",
"       11",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The reason for an association between LABD and ulcerative colitis is unclear. Some authors have suggested that abnormal IgA1 production by the inflamed bowel may contribute to the development of LABD [",
"      <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/49\">",
"       49",
"      </a>",
"      ]. Although improvement in skin disease following surgical intervention for bowel disease has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/50-52\">",
"       50-52",
"      </a>",
"      ], in other patients skin disease has persisted after surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Malignancy",
"      </strong>",
"      &ndash; The occurrence of LABD in association with lymphoproliferative and solid organ malignancies has been reported in multiple case reports [",
"      <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/25,53-70\">",
"       25,53-70",
"      </a>",
"      ]. However, further studies are necessary to confirm an association between LABD and malignancy. Thus, in the absence of signs or symptoms suggestive of a malignancy, screening beyond age-appropriate investigation is not warranted in patients with LABD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other disorders reported to occur in association with LABD in a few patients include a variety of infections [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/22,71-75\">",
"     22,71-75",
"    </a>",
"    ], psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/74,76\">",
"     74,76",
"    </a>",
"    ], and systemic lupus erythematosus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/11,77\">",
"     11,77",
"    </a>",
"    ]. The development of LABD has also been reported following exposure to ultraviolet light [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/22,78\">",
"     22,78",
"    </a>",
"    ]. Unlike dermatitis herpetiformis, which may clinically and histologically resemble LABD, gluten sensitivity is not a feature of this disorder and gluten-free diets do not improve LABD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/3,79\">",
"     3,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28759781\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical signs and symptoms of LABD may resemble multiple mucocutaneous diseases. Thus, when available, laboratory studies are typically utilized to confirm the diagnosis. Although the findings of routine histopathologic examination of affected tissue may suggest LABD, the demonstration of linear deposits of IgA along the basement membrane zone via direct immunofluorescence (DIF) is the gold standard for diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, a medication history should always be reviewed to assess for the possibility of drug-induced disease. (See",
"    <a class=\"local\" href=\"#H28759752\">",
"     'Drug-induced linear IgA'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H655769\">",
"    <span class=\"h2\">",
"     Light microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histopathologic findings of linear IgA bullous dermatosis are nonspecific and often closely resemble dermatitis herpetiformis. A subepidermal blister with an underlying neutrophil-predominant dermal infiltrate is characteristic (",
"    <a class=\"graphic graphic_picture graphicRef69124 \" href=\"UTD.htm?33/12/33991\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/3\">",
"     3",
"    </a>",
"    ]. Lymphocytes, eosinophils, and papillary microabscesses similar to those seen in dermatitis herpetiformis also may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14186?source=see_link&amp;anchor=H4714350#H4714350\">",
"     \"Approach to the patient with cutaneous blisters\", section on 'Skin biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H829103\">",
"    <span class=\"h2\">",
"     Direct immunofluorescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to perform direct immunofluorescence, a small biopsy (eg, 4 mm punch) is taken from perilesional skin (clinically normal appearing skin immediately adjacent to a lesion) and sent to an immunopathology laboratory in a preservative such as Michel&rsquo;s or Zeus medium or as a flash-frozen specimen. In situations in which the specimen can be delivered to the laboratory within minutes, transport on saline-moistened gauze is an alternative. Specimens for direct immunofluorescence should",
"    <strong>",
"     not",
"    </strong>",
"    be placed in formalin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14186?source=see_link&amp;anchor=H4714358#H4714358\">",
"     \"Approach to the patient with cutaneous blisters\", section on 'Direct immunofluorescence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic finding of LABD via direct immunofluorescence is a linear band of IgA at the dermoepidermal junction (",
"    <a class=\"graphic graphic_picture graphicRef76346 \" href=\"UTD.htm?12/44/12995\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/6\">",
"     6",
"    </a>",
"    ]. Utilization of the salt-split skin technique is not particularly useful for diagnosis since testing reveals variable results [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/11,80\">",
"     11,80",
"    </a>",
"    ]. Antibody binding to the epidermal side of the induced cleavage zone is most common; binding to the dermal side may be more likely to occur in patients who are older or who have both IgA and IgG deposits at the epidermal basement membrane zone [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/11\">",
"     11",
"    </a>",
"    ]. Binding to both epidermal and dermal sides of the plane of cleavage may also occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14186?source=see_link&amp;anchor=H320546#H320546\">",
"     \"Approach to the patient with cutaneous blisters\", section on 'Basement membrane zone-split skin technique'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H829212\">",
"    <span class=\"h2\">",
"     Indirect immunofluorescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indirect immunofluorescence can be used to detect circulating IgA antibodies against basement membrane zone components and may aid in diagnosis when a skin biopsy is not possible. This test is less likely to be positive in adults than in children (30 versus &ge;75 percent of patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/4,19\">",
"     4,19",
"    </a>",
"    ]. For best results, indirect immunofluorescence should be performed on a substrate of salt-split human skin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/7,80\">",
"     7,80",
"    </a>",
"    ]. In the vast majority of cases, indirect immunofluorescence studies reveal antibody bound to the epidermal side of salt-split skin, a finding that is consistent with the locations of the 97 kDa antigen, 120 kDa antigen, and BP180. (See",
"    <a class=\"local\" href=\"#H827478\">",
"     'Pathogenesis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14186?source=see_link&amp;anchor=H4714372#H4714372\">",
"     \"Approach to the patient with cutaneous blisters\", section on 'Indirect immunofluorescence'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H829219\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other tests such as immunoelectron microscopy and immunoblotting can also be used to confirm the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/3\">",
"     3",
"    </a>",
"    ]. However, the cost and limited availability of these tests limit their value in the clinical setting. We do not routinely utilize these studies for diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H829964\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute onset of widespread annular or arcuate blisters strongly suggests the possibility of LABD (",
"    <a class=\"graphic graphic_picture graphicRef56434 \" href=\"UTD.htm?15/62/16359\">",
"     picture 2E",
"    </a>",
"    ). However, annular lesions are not always present, and multiple other disorders share clinical features with LABD. Examples of conditions to consider in the differential diagnosis are provided below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dermatitis herpetiformis",
"      </strong>",
"      &ndash; Dermatitis herpetiformis is an autoimmune subepidermal blistering disorder with clinical and histopathologic features that can closely resemble LABD. Patients typically present with grouped vesicles or bullae on the scalp, extensor extremities, or buttocks (",
"      <a class=\"graphic graphic_picture graphicRef78315 \" href=\"UTD.htm?23/38/24163\">",
"       picture 6",
"      </a>",
"      ). Direct immunofluorescence microscopy is useful for distinguishing these disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35369?source=see_link\">",
"       \"Dermatitis herpetiformis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Bullous impetigo",
"      </strong>",
"      &ndash; Bullous impetigo is a",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      infection that most commonly occurs in young children. Multiple, easily-ruptured bullae with clear or yellow fluid are typically present on the face, trunk, or extremities (",
"      <a class=\"graphic graphic_picture graphicRef63992 \" href=\"UTD.htm?0/48/768\">",
"       picture 7",
"      </a>",
"      ). A collarette of scale often remains at the site of ruptured lesions. A culture of the fluid from an intact blister can be used to detect",
"      <em>",
"       S. aureus",
"      </em>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21846?source=see_link&amp;anchor=H4#H4\">",
"       \"Impetigo\", section on 'Bullous impetigo'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Bullous pemphigoid",
"      </strong>",
"      &ndash; Bullous pemphigoid is an autoimmune subepidermal blistering disorder that typically affects older adults and manifests as pruritic inflammatory plaques and bullae that are primarily distributed on the trunk and extremities (",
"      <a class=\"graphic graphic_picture graphicRef72866 graphicRef58359 graphicRef66179 \" href=\"UTD.htm?26/23/27002\">",
"       picture 8A-C",
"      </a>",
"      ). Histopathologic examination usually reveals a higher proportion of eosinophils than are present in LABD. Direct immunofluorescence in bullous pemphigoid usually reveals linear IgG and C3 deposits at the basement membrane zone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link&amp;anchor=H53290498#H53290498\">",
"       \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Bullous pemphigoid'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pemphigoid gestationis",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Pemphigoid gestationis is an autoimmune subepidermal blistering disorder that occurs in pregnant women. The pruritic eruption frequently begins around the umbilicus and subsequently spreads elsewhere (",
"      <a class=\"graphic graphic_picture graphicRef78383 graphicRef63947 graphicRef52776 \" href=\"UTD.htm?30/37/31320\">",
"       picture 9A-C",
"      </a>",
"      ). Direct immunofluorescence microscopy reveals the deposition of C3 in a linear pattern at the basement membrane zone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29657?source=see_link&amp;anchor=H2#H2\">",
"       \"Dermatoses of pregnancy\", section on 'Pemphigoid gestationis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Bullous lupus erythematosus",
"      </strong>",
"      &ndash; Bullous lupus erythematosus is a rare subepidermal blistering disorder. The presence of a bullous disorder in a patient with systemic lupus erythematosus suggests the possibility of this disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link&amp;anchor=H10#H10\">",
"       \"Mucocutaneous manifestations of systemic lupus erythematosus\", section on 'Bullous skin lesions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Epidermolysis bullosa acquisita",
"      </strong>",
"      &ndash; Epidermolysis bullosa acquisita is a rare acquired subepidermal blistering disorder of the skin and mucous membranes (",
"      <a class=\"graphic graphic_picture graphicRef62505 \" href=\"UTD.htm?21/36/22085\">",
"       picture 10",
"      </a>",
"      ). Scarring and milia are common associated features. On direct immunofluorescence, deposits of IgG are most commonly detected at the basement membrane zone; however, less commonly, other immunoglobulins (including IgA) may be present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4858?source=see_link\">",
"       \"Epidermolysis bullosa acquisita\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Mucous membrane pemphigoid",
"      </strong>",
"      &ndash; Mucous membrane pemphigoid consists of a group of subepidermal blistering disorders in which mucosal surfaces are the primary site of involvement. Mucosal-predominant LABD may be considered a form of mucous membrane pemphigoid. The immunofluorescence findings distinguish this subtype from other disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link&amp;anchor=H53290512#H53290512\">",
"       \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Mucous membrane pemphigoid'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infrequently, LABD may resemble prurigo nodularis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/27\">",
"     27",
"    </a>",
"    ], morbilliform drug eruptions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/41\">",
"     41",
"    </a>",
"    ], erythema multiforme [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/42\">",
"     42",
"    </a>",
"    ], or toxic epidermolytic necrolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. In addition, LABD in children may be mistaken for child abuse. (See",
"    <a class=\"local\" href=\"#H829252\">",
"     'Cutaneous lesions'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H28759752\">",
"     'Drug-induced linear IgA'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28759788\">",
"    <span class=\"h1\">",
"     THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the treatment options for LABD are limited. The approach to treatment is primarily based upon case reports and case series.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28761137\">",
"    <span class=\"h2\">",
"     First line therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    , an immunomodulatory sulfone that has been successfully utilized for the treatment of multiple dermatologic disorders characterized by neutrophilic infiltrates, is considered first-line treatment for LABD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/3,4,6,7,81\">",
"     3,4,6,7,81",
"    </a>",
"    ]. Dapsone has a long history of successful use in LABD and dermatitis herpetiformis, and is well-tolerated by most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3979336\">",
"    <span class=\"h3\">",
"     Dapsone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no controlled trials have evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    in children and adults with LABD, based upon case series, case reports, and clinical observations, the drug appears to be effective in many patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/11,27,29,82-86\">",
"     11,27,29,82-86",
"    </a>",
"    ]. As an example, in a retrospective study in which 19 children received dapsone (1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) as monotherapy, 11 patients (61 percent) attained lesion regression within 8 to 15 days [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    is started at a low dose (eg, &lt;0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in children or 25 or 50 mg per day in adults) that is titrated upward over several weeks as tolerated and in accordance with treatment response [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/87\">",
"     87",
"    </a>",
"    ]. In LABD, the response to treatment can be dramatic, with signs of improvement noted within the first few days of therapy.",
"   </p>",
"   <p>",
"    Typical dose ranges for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    therapy for LABD are listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Children",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      0.5 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day [",
"      <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/17,29,88\">",
"       17,29,88",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <strong>",
"       Adults",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      50 to 150 mg per day [",
"      <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/7,81\">",
"       7,81",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although most patients tolerate the drug well,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    must be administered with caution, since potential serious adverse effects, such as hemolysis, methemoglobinemia, agranulocytosis, hypersensitivity syndrome, and peripheral motor neuropathy may occur as a result of therapy. Hemolysis occurs to some degree in all patients, and frequent hematologic monitoring during the early stages of treatment is recommended.",
"   </p>",
"   <p>",
"    A complete blood count (CBC) with differential, liver function tests and glucose-6-phosphate dehydrogenase (G6PD) level should be obtained prior to the initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    . We typically follow the CBC with differential weekly for one month, and then decrease the frequency to every two weeks for an additional eight weeks. Liver function tests should be monitored monthly for first three months. For long-term monitoring we recommend obtaining a CBC with differential, renal function tests, and liver function tests every three to four months.",
"   </p>",
"   <p>",
"    Screening for glucose-6-phosphate (G6PD) deficiency should be performed prior to the initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    therapy. The administration of dapsone should be",
"    <strong>",
"     avoided",
"    </strong>",
"    in patients with G6PD deficiency since this disorder is associated with an elevated risk for the development of severe hemolytic anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\", section on 'Acute hemolytic anemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\", section on 'Methodology'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H986324\">",
"    <span class=\"h3\">",
"     Topical corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some authors have suggested that topical corticosteroids may be sufficient for disease control in patients with mild or localized LABD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/81,89\">",
"     81,89",
"    </a>",
"    ], most patients require systemic therapy to adequately control the disease. Thus, topical corticosteroids are primarily used as adjunctive therapy.",
"   </p>",
"   <p>",
"    High potency or superpotent topical corticosteroids applied to individual lesions once or twice daily for up to two weeks may be utilized to accelerate improvement in lesions on the trunk or extremities. Low potency agents are preferred for lesions on the face, genital, or intertriginous regions due to an increased risk for corticosteroid-induced cutaneous atrophy in these areas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3979368\">",
"    <span class=\"h2\">",
"     Second line therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who cannot tolerate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    may benefit from treatment with sulfapyridine or sulfamethoxypyridazine, sulfonamide agents that have structural similarities with dapsone [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/6\">",
"     6",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    is an additional therapeutic option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3979375\">",
"    <span class=\"h3\">",
"     Sulfonamides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence for the efficacy of sulfapyridine and sulfamethoxypyridazine are primarily limited to reports of expert clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/3,6,7,87,90\">",
"     3,6,7,87,90",
"    </a>",
"    ]. Formal therapeutic trials of these agents to confirm efficacy in LABD have not been performed. In one series, sulfamethoxypyridazine monotherapy (1000 mg per day) was associated with the attainment of disease control in three patients with LABD who discontinued",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    due to a failure to tolerate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/90\">",
"     90",
"    </a>",
"    ]. None of these patients were young children.",
"   </p>",
"   <p>",
"    Adults with LABD may be treated with 1000 to 1500 mg per day of sulfapyridine or sulfamethoxypyridazine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/7\">",
"     7",
"    </a>",
"    ]. Children have been treated with 15 to 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of sulfapyridine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. An appropriate dose range has not been established for sulfamethoxypyridazine treatment in children [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/3\">",
"     3",
"    </a>",
"    ]. These agents have also been used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    in patients with LABD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/6,90,91\">",
"     6,90,91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The availability of these agents is limited in some countries. In the United States, sulfapyridine can be obtained through compounding pharmacies, and sulfamethoxypyridazine is not available. The side effect profile of sulfapyridine is similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , but the toxicity is less, a feature that makes use of this agent possible in patients with dapsone intolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/92\">",
"     92",
"    </a>",
"    ]. Alveolitis is an additional side effect that has been reported in patients treated with sulfamethoxypyridazine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/90,93\">",
"     90,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monitoring guidelines for sulfapyridine and sulfamethoxypyridazine have not been established. During treatment with sulfapyridine, we typically obtain a CBC every three to six months to evaluate for leukopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H395675\">",
"    <span class=\"h3\">",
"     Colchicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful treatment of childhood LABD with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    has been documented in case reports and small case series and this agent may be another reasonable option for children who cannot tolerate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/83,94-97\">",
"     83,94-97",
"    </a>",
"    ]. In a series of eight children with systemic glucocorticoid-refractory LABD, the addition of colchicine to glucocorticoid therapy led to dramatic responses to therapy in five patients within four to six weeks. In addition, these patients tolerated tapering and discontinuation of glucocorticoid therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    has also been reported to be effective in a few adults with generalized or localized LABD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/23,98\">",
"     23,98",
"    </a>",
"    ]. However, the clinical experiences of some authors with adult patients have been less favorable [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The typical dosage for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    is 0.6 mg twice daily in children and 0.6 to 1 mg two to three times daily in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/3,4,94,95\">",
"     3,4,94,95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H658542\">",
"    <span class=\"h2\">",
"     Severe and refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive agents may be beneficial in patients with severe clinical manifestations or refractory disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H658549\">",
"    <span class=\"h3\">",
"     Immunosuppressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoids (eg, 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) may be used during the initial few weeks of treatment to accelerate improvement in patients with severe involvement while awaiting the response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/7,29,81,83\">",
"     7,29,81,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who fail to respond sufficiently to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    may also derive benefit from the addition of systemic glucocorticoids to dapsone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/7,84-87,99\">",
"     7,84-87,99",
"    </a>",
"    ]. However, due to the potential adverse effects of systemic glucocorticoids, these agents are not recommended for long term use. Glucocorticoid sparing agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/100-104\">",
"     100-104",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/105\">",
"     105",
"    </a>",
"    ] have been reported to be effective in small numbers of patients, and can be utilized when longer periods of immunosuppressive therapy are required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1097406\">",
"    <span class=\"h3\">",
"     Other interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immunoglobulin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/20,106-111\">",
"     20,106-111",
"    </a>",
"    ] and immunoadsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/112\">",
"     112",
"    </a>",
"    ] have been reported to be effective in a few patients with LABD. However, further studies are necessary to evaluate the efficacy of these interventions prior to a recommendation for their routine use in severe or refractory LABD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H656278\">",
"    <span class=\"h2\">",
"     Additional therapeutic options",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/27/38322?source=see_link\">",
"     nicotinamide",
"    </a>",
"    , and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    are utilized less frequently than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    for the treatment of LABD, but have been reported to be effective in small numbers of patients. Additional studies are necessary to confirm the efficacy of these therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3979491\">",
"    <span class=\"h3\">",
"     Systemic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports and small case series suggest that systemic antibiotics may be of benefit for childhood LABD. Whether antiinflammatory, antibacterial, or other properties of these agents contribute to treatment efficacy is unknown.",
"   </p>",
"   <p>",
"    In a series of seven children with LABD treated with flucloxacillin, disease clearance was achieved in all patients, but only four patients who received treatment early in the course of the disease (within one month of disease onset) had long-lasting remission off of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/71\">",
"     71",
"    </a>",
"    ]. Oxacillin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/29\">",
"     29",
"    </a>",
"    ], dicloxacillin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/113\">",
"     113",
"    </a>",
"    ], erythromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/84\">",
"     84",
"    </a>",
"    ], and miocamycin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/114\">",
"     114",
"    </a>",
"    ], all given at doses of 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, have additionally been reported to be of benefit in individual children [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/115\">",
"     115",
"    </a>",
"    ]. Erythromycin may also have been effective in an adult [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/116\">",
"     116",
"    </a>",
"    ]. Trimethoprim-sulfamethoxazole has been associated with both the induction and remission of LABD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/14,117-119\">",
"     14,117-119",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H395888\">",
"    <span class=\"h3\">",
"     Tetracycline and nicotinamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     Tetracycline",
"    </a>",
"    (1000 to 1500 mg per day) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/27/38322?source=see_link\">",
"     nicotinamide",
"    </a>",
"    (900 to 2000 mg per day), a drug combination that has been used for the treatment of bullous pemphigoid, was reported to induce disease clearance within a few weeks in three adult patients with LABD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/120-122\">",
"     120-122",
"    </a>",
"    ]. Of note, tetracycline cannot be utilized in children under the age of nine due to the drug&rsquo;s adverse effects on developing teeth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H396612\">",
"    <span class=\"h3\">",
"     Topical tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ointment, a topical calcineurin inhibitor, has been attempted in LABD. Disease resolution was observed in a child on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    therapy two weeks after her adjunctive topical therapy was changed from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    dipropionate 0.05% to tacrolimus 0.03% ointment applied twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/123\">",
"     123",
"    </a>",
"    ]. However, spontaneous resolution may also have accounted for the resolution of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10646217\">",
"    <span class=\"h2\">",
"     Drug-induced disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced LAD typically resolves with withdrawal of the offending agent. (See",
"    <a class=\"local\" href=\"#H656390\">",
"     'Prognosis and cessation of therapy'",
"    </a>",
"    below.) In severe or persistent cases, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    may be beneficial. Therapy should be tapered or discontinued early in the course of treatment (eg, within the first four to six weeks) to confirm the presence of active disease that necessitates the continuation of systemic treatment. Prolonged systemic treatment is rarely needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H656390\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND CESSATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic LABD typically persists for months to several years prior to spontaneous resolution, and resolves in most children prior to puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/2,4,99\">",
"     2,4,99",
"    </a>",
"    ]. However, disease may persist for a decade or longer, and relapses after long periods of remission may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/99\">",
"     99",
"    </a>",
"    ]. In contrast, in drug-induced LABD, cessation of new lesion formation typically occurs within three days of removal of the inciting agent and disease resolution usually occurs within several weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The duration of treatment required for idiopathic LABD is variable. Treatment with an effective agent is usually continued for several weeks after complete remission is attained, and subsequently, gradual tapering towards treatment cessation is attempted [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/7,99\">",
"     7,99",
"    </a>",
"    ]. If relapse occurs after treatment cessation, treatment should be reinitiated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/36/14922/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although cutaneous lesions usually heal without permanent scars, patients with mucosal involvement may experience morbidity and functional limitations due to stricture formation or conjunctival and corneal scarring. Consequences related to poor oral hygiene and alimentation may also occur in patients with oral disease. (See",
"    <a class=\"local\" href=\"#H28759745\">",
"     'Mucosal involvement'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H656834\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;A dermatologist or another clinician familiar with the management of LABD should be involved in the care of these patients. Patients with signs or symptoms of ocular disease should be referred to an ophthalmologist. In addition, consultation with an otolaryngologist or gastroenterologist is appropriate for patients with symptoms suggestive of pharyngeal, laryngeal, or esophageal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H656896\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Linear IgA bullous dermatosis (LABD) is a rare autoimmune blistering disorder that usually presents with the abrupt onset of tense bullae and inflammatory lesions on the skin. Both children and adults may be affected. (See",
"      <a class=\"local\" href=\"#H28759731\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases of LABD are idiopathic. However, LABD has also been reported in association with drug exposure.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      is the pharmacologic agent most frequently associated with LABD. (See",
"      <a class=\"local\" href=\"#H1919394\">",
"       'Risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28759752\">",
"       'Drug-induced linear IgA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with LABD frequently develop widespread annular or arciform blisters that are often most abundant on the groin, lower abdomen, and medial thighs. In adults, the annular lesions are less commonly detected, and the trunk and extremities are typical sites of involvement. Pruritus is a common symptom of LABD. (See",
"      <a class=\"local\" href=\"#H829252\">",
"       'Cutaneous lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mucosal involvement in LABD may affect any mucosal site. Examples of potential serious consequences of mucosal involvement include blindness, airway obstruction, and esophageal strictures. (See",
"      <a class=\"local\" href=\"#H28759745\">",
"       'Mucosal involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The gold standard for the diagnosis of LABD is the detection of linear deposits of IgA with direct immunofluorescence microscopy. The tissue specimen for direct immunofluorescence should be taken from perilesional skin. The specimen must",
"      <strong>",
"       not",
"      </strong>",
"      be placed in formalin. (See",
"      <a class=\"local\" href=\"#H28759781\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14186?source=see_link&amp;anchor=H4714358#H4714358\">",
"       \"Approach to the patient with cutaneous blisters\", section on 'Direct immunofluorescence'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Data on the treatment options for LABD are primarily limited to case reports and case series. For children and adults with LABD, we suggest the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The response to therapy is usually evident within days. Sulfapyridine, sulfamethoxypyridazine, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      are additional options for patients who cannot tolerate dapsone therapy. (See",
"      <a class=\"local\" href=\"#H28759788\">",
"       'Therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunosuppressive therapy may be employed for patients with LABD that is refractory to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      or sulfonamide therapy. Use of a glucocorticoid-sparing agent such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil is recommended when long term immunosuppression is required. (See",
"      <a class=\"local\" href=\"#H658542\">",
"       'Severe and refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/1\">",
"      Lawley TJ, Strober W, Yaoita H, Katz SI. Small intestinal biopsies and HLA types in dermatitis herpetiformis patients with granular and linear IgA skin deposits. J Invest Dermatol 1980; 74:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/2\">",
"      Wojnarowska F, Marsden RA, Bhogal B, Black MM. Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults. A comparative study demonstrating clinical and immunopathologic overlap. J Am Acad Dermatol 1988; 19:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/3\">",
"      Fortuna G, Marinkovich MP. Linear immunoglobulin A bullous dermatosis. Clin Dermatol 2012; 30:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/4\">",
"      Mintz EM, Morel KD. Clinical features, diagnosis, and pathogenesis of chronic bullous disease of childhood. Dermatol Clin 2011; 29:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/5\">",
"      Gluth MB, Witman PM, Thompson DM. Upper aerodigestive tract complications in a neonate with linear IgA bullous dermatosis. Int J Pediatr Otorhinolaryngol 2004; 68:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/6\">",
"      Guide SV, Marinkovich MP. Linear IgA bullous dermatosis. Clin Dermatol 2001; 19:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/7\">",
"      Chorzelski TP, Jaboska S, Maciejowska E. Linear IgA bullous dermatosis of adults. Clin Dermatol 1991; 9:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/8\">",
"      Ishii N, Ohyama B, Yamaguchi Z, Hashimoto T. IgA autoantibodies against the NC16a domain of BP180 but not 120-kDa LAD-1 detected in a patient with linear IgA disease. Br J Dermatol 2008; 158:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/9\">",
"      Zillikens D, Herzele K, Georgi M, et al. Autoantibodies in a subgroup of patients with linear IgA disease react with the NC16A domain of BP1801. J Invest Dermatol 1999; 113:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/10\">",
"      Lin MS, Fu CL, Olague-Marchan M, et al. Autoimmune responses in patients with linear IgA bullous dermatosis: both autoantibodies and T lymphocytes recognize the NC16A domain of the BP180 molecule. Clin Immunol 2002; 102:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/11\">",
"      Horiguchi Y, Ikoma A, Sakai R, et al. Linear IgA dermatosis: report of an infantile case and analysis of 213 cases in Japan. J Dermatol 2008; 35:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/12\">",
"      Fortuna G, Salas-Alanis JC, Guidetti E, Marinkovich MP. A critical reappraisal of the current data on drug-induced linear immunoglobulin A bullous dermatosis: a real and separate nosological entity? J Am Acad Dermatol 2012; 66:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/13\">",
"      Ho JC, Ng PL, Tan SH, Giam YC. Childhood linear IgA bullous disease triggered by amoxicillin-clavulanic acid. Pediatr Dermatol 2007; 24:E40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/14\">",
"      Polat M, Lenk N, K&uuml;rek&ccedil;i E, et al. Chronic bullous disease of childhood in a patient with acute lymphoblastic leukemia: possible induction by a drug. Am J Clin Dermatol 2007; 8:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/15\">",
"      Kocyigit P, Akay BN, Karaosmanoglu N. Linear IgA bullous dermatosis induced by interferon-alpha 2a. Clin Exp Dermatol 2009; 34:e123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/16\">",
"      Collier PM, Wojnarowska F, Welsh K, et al. Adult linear IgA disease and chronic bullous disease of childhood: the association with human lymphocyte antigens Cw7, B8, DR3 and tumour necrosis factor influences disease expression. Br J Dermatol 1999; 141:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/17\">",
"      Lara-Corrales I, Pope E. Autoimmune blistering diseases in children. Semin Cutan Med Surg 2010; 29:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/18\">",
"      Marsden RA, McKee PH, Bhogal B, et al. A study of benign chronic bullous dermatosis of childhood and comparison with dermatitis herpetiformis and bullous pemphigoid occurring in childhood. Clin Exp Dermatol 1980; 5:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/19\">",
"      Venning VA. Linear IgA disease: clinical presentation, diagnosis, and pathogenesis. Dermatol Clin 2011; 29:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/20\">",
"      Cauza K, Hinterhuber G, Sterniczky B, et al. Unusual clinical manifestation of linear IgA dermatosis: a report of two cases. J Am Acad Dermatol 2004; 51:S112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/21\">",
"      Gamo R, Aguilar A, G&oacute;nzalez-Valle O, et al. Localized linear IgA disease associated with monoclonal gammapathy of undetermined significance. J Eur Acad Dermatol Venereol 2007; 21:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/22\">",
"      He C, Xu H, Xiao T, et al. Localized linear IgA dermatosis induced by UV light-treatment for herpes zoster. Int J Dermatol 2007; 46:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/23\">",
"      Benbenisty KM, Bowman PH, Davis LS. Localized linear IgA disease responding to colchicine. Int J Dermatol 2002; 41:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/24\">",
"      Shimanovich I, Rose C, Sitaru C, et al. Localized linear IgA disease induced by ampicillin/sulbactam. J Am Acad Dermatol 2004; 51:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/25\">",
"      Dippel E, Orfanos CE, Zouboulis C. Linear IgA dermatosis presenting with erythema annulare centrifugum lesions: report of three cases in adults. J Eur Acad Dermatol Venereol 2001; 15:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/26\">",
"      Caputo R, Bencini PL, Vigo GP, et al. Eruption resembling erythema gyratum repens in linear IgA dermatosis. Dermatology 1995; 190:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/27\">",
"      Torchia D, Caproni M, Del Bianco E, et al. Linear IgA disease presenting as prurigo nodularis. Br J Dermatol 2006; 155:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/28\">",
"      Torchia D, Caproni M, Cozzani E, et al. Subacute prurigo-like linear IgA disease. Int J Dermatol 2007; 46:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/29\">",
"      Kenani N, Mebazaa A, Denguezli M, et al. Childhood linear IgA bullous dermatosis in Tunisia. Pediatr Dermatol 2009; 26:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/30\">",
"      Angiero F, Benedicenti S, Crippa R, et al. A rare case of desquamative gingivitis due to linear IgA disease: morphological and immunofluorescence features. In Vivo 2007; 21:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/31\">",
"      Kelly SE, Frith PA, Millard PR, et al. A clinicopathological study of mucosal involvement in linear IgA disease. Br J Dermatol 1988; 119:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/32\">",
"      Talhari C, Althaus C, Megahed M. Ocular linear IgA disease resulting in blindness. Arch Dermatol 2006; 142:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/33\">",
"      Sato K, Hanazawa H, Sato Y, Watanabe J. Initial presentation and fatal complications of linear IgA bullous dermatosis in the larynx and pharynx. J Laryngol Otol 2005; 119:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/34\">",
"      Sertznig P, Megahed M. [Linear IgA disease of the oral mucosa with pharyngeal and esophageal involvement]. Hautarzt 2010; 61:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/35\">",
"      del Valle AE, Mart&iacute;nez-Sahuquillo A, Padr&oacute;n JR, Urizar JM. Two cases of linear IgA disease with clinical manifestations limited to the gingiva. J Periodontol 2003; 74:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/36\">",
"      Torchia D, Caproni M, Fabbri P. Linear IgA disease and desquamative gingivitis: time for inclusion in mucous membrane pemphigoid. Oral Dis 2008; 14:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/37\">",
"      Chan LS, Regezi JA, Cooper KD. Oral manifestations of linear IgA disease. J Am Acad Dermatol 1990; 22:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/38\">",
"      Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/39\">",
"      Khan I, Hughes R, Curran S, Marren P. Drug-associated linear IgA disease mimicking toxic epidermal necrolysis. Clin Exp Dermatol 2009; 34:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/40\">",
"      Waldman MA, Black DR, Callen JP. Vancomycin-induced linear IgA bullous disease presenting as toxic epidermal necrolysis. Clin Exp Dermatol 2004; 29:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/41\">",
"      Billet SE, Kortuem KR, Gibson LE, El-Azhary R. A morbilliform variant of vancomycin-induced linear IgA bullous dermatosis. Arch Dermatol 2008; 144:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/42\">",
"      Armstrong AW, Fazeli A, Yeh SW, et al. Vancomycin-induced linear IgA disease manifesting as bullous erythema multiforme. J Cutan Pathol 2004; 31:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/43\">",
"      McDonald HC, York NR, Pandya AG. Drug-induced linear IgA bullous dermatosis demonstrating the isomorphic phenomenon. J Am Acad Dermatol 2010; 62:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/44\">",
"      Walsh SN, Kerchner K, Sang&uuml;eza OP. Localized palmar vancomycin-induced linear IgA bullous dermatosis occurring at supratherapeutic levels. Arch Dermatol 2009; 145:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/45\">",
"      Nousari HC, Costarangos C, Anhalt GJ. Vancomycin-associated linear IgA bullous dermatosis. Ann Intern Med 1998; 129:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/46\">",
"      Navi D, Michael DJ, Fazel N. Drug-induced linear IgA bullous dermatosis. Dermatol Online J 2006; 12:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/47\">",
"      Whitworth JM, Thomas I, Peltz SA, et al. Vancomycin-induced linear IgA bullous dermatosis (LABD). J Am Acad Dermatol 1996; 34:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/48\">",
"      Taniguchi T, Maejima H, Saito N, et al. Case of linear IgA bullous dermatosis-involved ulcerative colitis. Inflamm Bowel Dis 2009; 15:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/49\">",
"      Paige DG, Leonard JN, Wojnarowska F, Fry L. Linear IgA disease and ulcerative colitis. Br J Dermatol 1997; 136:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/50\">",
"      Caldarola G, Annese V, Bossa F, Pellicano R. Linear IgA bullous dermatosis and ulcerative colitis treated by proctocolectomy. Eur J Dermatol 2009; 19:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/51\">",
"      Egan CA, Meadows KP, Zone JJ. Ulcerative colitis and immunobullous disease cured by colectomy. Arch Dermatol 1999; 135:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/52\">",
"      Walker SL, Banerjee P, Harland CC, Black MM. Remission of linear IgA disease associated with ulcerative colitis following panproclocolectomy. Br J Dermatol 2000; 143:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/53\">",
"      Holl&oacute; P, Preisz K, Nemes L, et al. Linear IgA dermatosis associated with chronic clonal myeloproliferative disease. Int J Dermatol 2003; 42:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/54\">",
"      Keller AS, Bouldin MB, Drage LA, et al. Linear IgA bullous dermatosis: an association with ulcerative colitis versus renal cell carcinoma. Dig Dis Sci 2003; 48:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/55\">",
"      Godfrey K, Wojnarowska F, Leonard J. Linear IgA disease of adults: association with lymphoproliferative malignancy and possible role of other triggering factors. Br J Dermatol 1990; 123:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/56\">",
"      Gantzer A, Bouaziz JD, Valeyrie-Allanore L, et al. [Acute linear IgA bullous dermatosis with circulating IgA monoclonal antibody associated with Hodgkin's disease]. Ann Dermatol Venereol 2010; 137:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/57\">",
"      Yhim HY, Kwon DH, Lee NR, et al. Linear IgA bullous dermatosis following autologous PBSC transplantation in a patient with non-Hodgkin's lymphoma. Bone Marrow Transplant 2011; 46:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/58\">",
"      Nassar D, Gabillot-Carr&eacute; M, Ortonne N, et al. Atypical linear IgA dermatosis revealing angioimmunoblastic T-cell lymphoma. Arch Dermatol 2009; 145:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/59\">",
"      Kano Y, Kokaji T, Shiohara T. Linear IgA bullous dermatosis in a patient with acute lymphocytic leukemia: possible involvement of granulocyte colony-stimulating factor. Eur J Dermatol 1999; 9:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/60\">",
"      Kapur A, Isaacs PE, Kelsey PR. Linear IgA dermatosis, coeliac disease, and extraintestinal B cell lymphoma. Gut 1995; 37:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/61\">",
"      Jouan N, Plantin P, Berthou C, et al. [Association of IgA linear dermatitis and non-Hodgkin's malignant lymphoma]. Rev Med Interne 1992; 13:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/62\">",
"      Jacyk WK, Nagel GJ, van der Hoven AE. Linear IgA dermatosis and Hodgkin's lymphoma--report of a case in an African and review of the literature. J Dermatol 1990; 17:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/63\">",
"      Barnadas MA, Moreno A, Brunet S, et al. Linear IgA bullous dermatosis associated with Hodgkin's disease. J Am Acad Dermatol 1988; 19:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/64\">",
"      Adamic M, Potocnik M, Pavlovi MD. Linear IgA bullous dermatosis in a patient with advanced pancreatic carcinoma. Clin Exp Dermatol 2008; 33:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/65\">",
"      Lai-Cheong JE, Groves RW, Banerjee P. Linear IgA bullous dermatosis associated with adenocarcinoma of the ascending colon. J Eur Acad Dermatol Venereol 2007; 21:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/66\">",
"      Usmani N, Baxter KF, Child JA, Sheehan-Dare R. Linear IgA disease in association with chronic lymphocytic leukaemia. Br J Dermatol 2004; 151:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/67\">",
"      van der Waal RI, van de Scheur MR, Pas HH, et al. Linear IgA bullous dermatosis in a patient with renal cell carcinoma. Br J Dermatol 2001; 144:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/68\">",
"      R&oacute;denas JM, Herranz MT, Tercedor J, Concha A. Linear IgA disease in a patient with bladder carcinoma. Br J Dermatol 1997; 136:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/69\">",
"      Lacour JP, Vitetta A, Ortonne JP. Linear IgA dermatosis and thyroid carcinoma. J Am Acad Dermatol 1992; 26:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/70\">",
"      McEvoy MT, Connolly SM. Linear IgA dermatosis: association with malignancy. J Am Acad Dermatol 1990; 22:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/71\">",
"      Alajlan A, Al-Khawajah M, Al-Sheikh O, et al. Treatment of linear IgA bullous dermatosis of childhood with flucloxacillin. J Am Acad Dermatol 2006; 54:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/72\">",
"      Sillevis Smitt JH, Leusen JH, Stas HG, et al. Chronic bullous disease of childhood and a paecilomyces lung infection in chronic granulomatous disease. Arch Dis Child 1997; 77:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/73\">",
"      Baldari U, Raccagni AA, Celli B, Righini MG. Chronic bullous disease of childhood following Epstein-Barr virus seroconversion: a case report. Clin Exp Dermatol 1996; 21:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/74\">",
"      Cooke N, Jenkinson H, Wojnarowska F, et al. Coexistence of psoriasis and linear IgA disease in a patient with recent herpes zoster infection. Clin Exp Dermatol 2005; 30:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/75\">",
"      Simon JC, Dietrich A, Kapp A, Sch&ouml;pf E. [Chronic bullous dermatosis in childhood. Association with salmonella enteritis]. Hautarzt 1995; 46:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/76\">",
"      Takagi Y, Sawada S, Yamauchi M, et al. Coexistence of psoriasis and linear IgA bullous dermatosis. Br J Dermatol 2000; 142:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/77\">",
"      Tob&oacute;n GJ, Toro CE, Bravo JC, Ca&ntilde;as CA. Linear IgA bullous dermatosis associated with systemic lupus erythematosus: a case report. Clin Rheumatol 2008; 27:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/78\">",
"      Salmhofer W, Soyer HP, Wolf P, et al. UV light-induced linear IgA dermatosis. J Am Acad Dermatol 2004; 50:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/79\">",
"      Leonard JN, Griffiths CE, Powles AV, et al. Experience with a gluten free diet in the treatment of linear IgA disease. Acta Derm Venereol 1987; 67:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/80\">",
"      Wojnarowska F, Collier PM, Allen J, Millard PR. The localization of the target antigens and antibodies in linear IgA disease is heterogeneous, and dependent on the methods used. Br J Dermatol 1995; 132:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/81\">",
"      Ng SY, Venning VV. Management of linear IgA disease. Dermatol Clin 2011; 29:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/82\">",
"      Wojnarowska F. Linear IgA dapsone responsive bullous dermatosis. J R Soc Med 1980; 73:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/83\">",
"      Ang P, Goh BK, Giam YC. Case reports of linear IgA bullous dermatosis of childhood. Ann Acad Med Singapore 1999; 28:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/84\">",
"      Monia K, Aida K, Amel K, et al. Linear IgA bullous dermatosis in tunisian children: 31 cases. Indian J Dermatol 2011; 56:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/85\">",
"      Nanda A, Dvorak R, Al-Sabah H, Alsaleh QA. Linear IgA bullous disease of childhood: an experience from Kuwait. Pediatr Dermatol 2006; 23:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/86\">",
"      Kharfi M, Khaled A, Karaa A, et al. Linear IgA bullous dermatosis: the more frequent bullous dermatosis of children. Dermatol Online J 2010; 16:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/87\">",
"      Wojnarowska F, Kirtschig G, Khumalo N. Treatment of subepidermal immunobullous diseases. Clin Dermatol 2001; 19:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/88\">",
"      Mintz EM, Morel KD. Treatment of chronic bullous disease of childhood. Dermatol Clin 2011; 29:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/89\">",
"      Culton DA, Diaz LA. Treatment of subepidermal immunobullous diseases. Clin Dermatol 2012; 30:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/90\">",
"      McFadden JP, Leonard JN, Powles AV, et al. Sulphamethoxypyridazine for dermatitis herpetiformis, linear IgA disease and cicatricial pemphigoid. Br J Dermatol 1989; 121:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/91\">",
"      Aboobaker J, Wojnarowska FT, Bhogal B, Black MM. Chronic bullous dermatosis of childhood--clinical and immunological features seen in African patients. Clin Exp Dermatol 1991; 16:160.",
"     </a>",
"    </li>",
"    <li>",
"     Hall RP, Mickle CP. Dapsone. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE.  (Ed), Elsevier Inc., Philadelphia 2007. p.239.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/93\">",
"      Godfrey KM, Wojnarowska F, Friedland JS. Obliterative bronchiolitis and alveolitis associated with sulphamethoxypyridazine (Lederkyn) therapy for linear IgA disease of adults. Br J Dermatol 1990; 123:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/94\">",
"      Ang P, Tay YK. Treatment of linear IgA bullous dermatosis of childhood with colchicine. Pediatr Dermatol 1999; 16:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/95\">",
"      Zeharia A, Hodak E, Mukamel M, et al. Successful treatment of chronic bullous dermatosis of childhood with colchicine. J Am Acad Dermatol 1994; 30:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/96\">",
"      Tay YK, Ang P. Treatment of linear IgA bullous dermatosis of childhood with colchicine: in reply. Pediatr Dermatol 2000; 17:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/97\">",
"      Banodkar DD, al-Suwaid AR. Colchicine as a novel therapeutic agent in chronic bullous dermatosis of childhood. Int J Dermatol 1997; 36:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/98\">",
"      Aram H. Linear IgA bullous dermatosis. Successful treatment with colchicine. Arch Dermatol 1984; 120:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/99\">",
"      Jaboska S, Chorzelski TP, Rosinska D, Maciejowska E. Linear IgA bullous dermatosis of childhood (chronic bullous dermatosis of childhood). Clin Dermatol 1991; 9:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/100\">",
"      Farley-Li J, Mancini AJ. Treatment of linear IgA bullous dermatosis of childhood with mycophenolate mofetil. Arch Dermatol 2003; 139:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/101\">",
"      Talhari C, Mahnke N, Ruzicka T, Megahed M. Successful treatment of linear IgA disease with mycophenolate mofetil as a corticosteroid sparing agent. Clin Exp Dermatol 2005; 30:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/102\">",
"      Lewis MA, Yaqoob NA, Emanuel C, Potts AJ. Successful treatment of oral linear IgA disease using mycophenolate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/103\">",
"      Gl&auml;ser R, Sticherlin M. Successful treatment of linear IgA bullous dermatosis with mycophenolate mofetil. Acta Derm Venereol 2002; 82:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/104\">",
"      Marzano AV, Ramoni S, Spinelli D, et al. Refractory linear IgA bullous dermatosis successfully treated with mycophenolate sodium. J Dermatolog Treat 2008; 19:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/105\">",
"      Young HS, Coulson IH. Linear IgA disease: successful treatment with cyclosporin. Br J Dermatol 2000; 143:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/106\">",
"      Goebeler M, Seitz C, Rose C, et al. Successful treatment of linear IgA disease with salazosulphapyridine and intravenous immunoglobulins. Br J Dermatol 2003; 149:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/107\">",
"      Letko E, Bhol K, Foster CS, Ahmed AR. Linear IgA bullous disease limited to the eye: a diagnostic dilemma: response to intravenous immunoglobulin therapy. Ophthalmology 2000; 107:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/108\">",
"      Khan IU, Bhol KC, Ahmed AR. Linear IgA bullous dermatosis in a patient with chronic renal failure: response to intravenous immunoglobulin therapy. J Am Acad Dermatol 1999; 40:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/109\">",
"      Kroiss MM, Vogt T, Landthaler M, Stolz W. High-dose intravenous immune globulin is also effective in linear IgA disease. Br J Dermatol 2000; 142:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/110\">",
"      Wetter DA, Davis MD, Yiannias JA, et al. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience. Mayo Clin Proc 2005; 80:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/111\">",
"      Segura S, Iranzo P, Mart&iacute;nez-de Pablo I, et al. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases. J Am Acad Dermatol 2007; 56:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/112\">",
"      Kasperkiewicz M, Meier M, Zillikens D, Schmidt E. Linear IgA disease: successful application of immunoadsorption and review of the literature. Dermatology 2010; 220:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/113\">",
"      Siegfried EC, Sirawan S. Chronic bullous disease of childhood: successful treatment with dicloxacillin. J Am Acad Dermatol 1998; 39:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/114\">",
"      Mervic L, Dragos V, Pavlovi MD. Linear IgA bullous dermatosis of childhood: successful treatment with miocamycin and topical corticosteroid. Clin Exp Dermatol 2009; 34:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/115\">",
"      Farrant P, Darley C, Carmichael A. Is erythromycin an effective treatment for chronic bullous disease of childhood? A national survey of members of the British Society for Paediatric Dermatology. Pediatr Dermatol 2008; 25:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/116\">",
"      Cooper SM, Powell J, Wojnarowska F. Linear IgA disease: successful treatment with erythromycin. Clin Exp Dermatol 2002; 27:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/117\">",
"      Peterson JD, Chan LS. Linear IgA bullous dermatosis responsive to trimethoprim-sulfamethoxazole. Clin Exp Dermatol 2007; 32:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/118\">",
"      Nantel-Battista M, Al Dhaybi R, Hatami A, et al. Childhood linear IgA bullous disease induced by trimethoprim-sulfamethoxazole. J Dermatol Case Rep 2010; 4:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/119\">",
"      Pulimood S, Ajithkumar K, Jacob M, et al. Linear IgA bullous dermatosis of childhood: treatment with dapsone and co-trimoxazole. Clin Exp Dermatol 1997; 22:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/120\">",
"      Chaffins ML, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J Am Acad Dermatol 1993; 28:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/121\">",
"      Peoples D, Fivenson DP. Linear IgA bullous dermatosis: successful treatment with tetracycline and nicotinamide. J Am Acad Dermatol 1992; 26:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/122\">",
"      Yomada M, Komai A, Hashimato T. Sublamina densa-type linear IgA bullous dermatosis successfully treated with oral tetracycline and niacianamide. Br J Dermatol 1999; 141:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/36/14922/abstract/123\">",
"      Dauendorffer JN, Mah&eacute; E, Saiag P. Tacrolimus ointment, an interesting adjunctive therapy for childhood linear IgA bullous dermatosis. J Eur Acad Dermatol Venereol 2008; 22:364.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15301 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-FFF4911520-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_36_14922=[""].join("\n");
var outline_f14_36_14922=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H656896\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28759724\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28759731\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H827478\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1919394\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28759738\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H829252\">",
"      Cutaneous lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28759745\">",
"      Mucosal involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28759752\">",
"      Drug-induced linear IgA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28759759\">",
"      ASSOCIATED DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28759781\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H655769\">",
"      Light microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H829103\">",
"      Direct immunofluorescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H829212\">",
"      Indirect immunofluorescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H829219\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H829964\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28759788\">",
"      THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28761137\">",
"      First line therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3979336\">",
"      - Dapsone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H986324\">",
"      - Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3979368\">",
"      Second line therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3979375\">",
"      - Sulfonamides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H395675\">",
"      - Colchicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H658542\">",
"      Severe and refractory disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H658549\">",
"      - Immunosuppressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1097406\">",
"      - Other interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H656278\">",
"      Additional therapeutic options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3979491\">",
"      - Systemic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H395888\">",
"      - Tetracycline and nicotinamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H396612\">",
"      - Topical tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10646217\">",
"      Drug-induced disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H656390\">",
"      PROGNOSIS AND CESSATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H656834\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H656896\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/15301\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15301|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/2/20516\" title=\"picture 1A\">",
"      Linear IgA bullous dermatosis of childhood on face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/48/15108\" title=\"picture 1B\">",
"      Linear IgA bullous dermatosis of childhood close view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/40/2693\" title=\"picture 1C\">",
"      Linear IgA bullous dermatosis of childhood on genitalia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/16/43267\" title=\"picture 1D\">",
"      Chronic bullous disease of childhood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/10/23716\" title=\"picture 2A\">",
"      Linear IgA bullous dermatosis on face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/23/16757\" title=\"picture 2B\">",
"      Linear IgA bullous dermatosis close view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/43/37557\" title=\"picture 2C\">",
"      Linear IgA bullous dermatosis on arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/49/7954\" title=\"picture 2D\">",
"      Linear IgA bullous dermatosis on extremity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/62/16359\" title=\"picture 2E\">",
"      Linear IgA bullous dermatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/52/42823\" title=\"picture 3\">",
"      Linear IgA bullous dermatosis resembling TEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/12/33991\" title=\"picture 4\">",
"      Pathology of linear IgA bullous dermatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/44/12995\" title=\"picture 5\">",
"      DIF of linear IgA bullous dermatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/38/24163\" title=\"picture 6\">",
"      Dermatitis herpetiformis elbows",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/48/768\" title=\"picture 7\">",
"      Bullous impetigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/16/26885\" title=\"picture 8A\">",
"      Bullous pemphigoid multiple lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/29/15827\" title=\"picture 8B\">",
"      Bullous pemphigoid in childhood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/58/32675\" title=\"picture 8C\">",
"      Bullous pemphigoid oral mucosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/56/20353\" title=\"picture 9A\">",
"      Pemphigoid gestationis umb",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/50/25376\" title=\"picture 9B\">",
"      Pemphigoid gestationis abd",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/34/29216\" title=\"picture 9C\">",
"      Pemphigoid gestationis ext",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/36/22085\" title=\"picture 10\">",
"      Epidermolysis bullosa acquisita",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15301|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/26/7596\" title=\"table 1\">",
"      Drug-induced linear IgA bullous dermatosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14186?source=related_link\">",
"      Approach to the patient with cutaneous blisters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=related_link\">",
"      Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=related_link\">",
"      Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35369?source=related_link\">",
"      Dermatitis herpetiformis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29657?source=related_link\">",
"      Dermatoses of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=related_link\">",
"      Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15273?source=related_link\">",
"      Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4858?source=related_link\">",
"      Epidermolysis bullosa acquisita",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21846?source=related_link\">",
"      Impetigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/2/4138?source=related_link\">",
"      Ocular cicatricial pemphigoid",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_36_14923="Ross heart failure classification for children";
var content_f14_36_14923=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modified Ross heart failure classification for children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asymptomatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild tachypnea or diaphoresis with feeding in infants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dyspnea on exertion in older children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marked tachypnea or diaphoresis with feeding in infants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged feeding times with growth failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marked dyspnea on exertion in older children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms such as tachypnea, retractions, grunting, or diaphoresis at rest",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Rosenthal D, Chrisant MR, Edens E, et al. International Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in children. J Heart Lung Transplant 2004; 23:1313. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_36_14923=[""].join("\n");
var outline_f14_36_14923=null;
var title_f14_36_14924="Drugs inducing pseudoporphyria";
var content_f14_36_14924=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs and chemicals inducing pseudoporphyria",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Antibiotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nalidixic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tetracycline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ciprofloxacin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Nonsteroidal antiinflammatory drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Naproxen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nabumetone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxaprozin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ketoprofen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mefenamic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diflusinal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Celecoxib",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diuretics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Furosemide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlorthalidone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrochlorothiazide/triamterene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bumetanide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Torsemide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Retinoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isotretinoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etretinate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imatinib",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclosporine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-Fluorouracil (intravenous)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carisoprodol/aspirin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyridoxine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amiodarone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flutamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dapsone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bakers' yeast",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral contraceptives",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_36_14924=[""].join("\n");
var outline_f14_36_14924=null;
var title_f14_36_14925="Babesia seroprevalence";
var content_f14_36_14925=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Seroprevalence of babesiosis by area, year, and time of year",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Region",
"      </td>",
"      <td class=\"subtitle1\">",
"       Timeframe",
"      </td>",
"      <td class=\"subtitle1\">",
"       Demographic",
"      </td>",
"      <td class=\"subtitle1\">",
"       Seroprevalence",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Nantucket Island",
"      </td>",
"      <td>",
"       August 1975 to July 1976",
"       <sup>",
"        [1]",
"       </sup>",
"      </td>",
"      <td>",
"       History of tick bite or fever for &ge;3 days",
"      </td>",
"      <td>",
"       7.5 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       August 1975 to July 1976",
"       <sup>",
"        [1]",
"       </sup>",
"      </td>",
"      <td>",
"       Residents and visitors",
"      </td>",
"      <td>",
"       1.9 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cape Cod",
"      </td>",
"      <td>",
"       Summer 1984",
"       <sup>",
"        [2]",
"       </sup>",
"      </td>",
"      <td>",
"       Blood donors",
"      </td>",
"      <td>",
"       3.7 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Block Island",
"      </td>",
"      <td>",
"       September 1990 to February 1991",
"       <sup>",
"        [3,4]",
"       </sup>",
"      </td>",
"      <td>",
"       Residents",
"      </td>",
"      <td>",
"       4.6 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Biannual serosurveys at beginning of summer and in the fall of 1999 and 2000)",
"       <sup>",
"        [5]",
"       </sup>",
"      </td>",
"      <td>",
"       Residents",
"      </td>",
"      <td>",
"       9 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Southern Connecticut",
"      </td>",
"      <td>",
"       July 1999",
"       <sup>",
"        [6]",
"       </sup>",
"      </td>",
"      <td>",
"       Blood donors",
"      </td>",
"      <td>",
"       1.9 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fall 1999",
"       <sup>",
"        [6]",
"       </sup>",
"      </td>",
"      <td>",
"       Blood donors",
"      </td>",
"      <td>",
"       0.5 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Year 2000",
"       <sup>",
"        [5]",
"       </sup>",
"      </td>",
"      <td>",
"       Blood donors",
"      </td>",
"      <td>",
"       9 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hartford County, Connecticut",
"      </td>",
"      <td>",
"       Summer and fall 1999",
"       <sup>",
"        [6]",
"       </sup>",
"      </td>",
"      <td>",
"       Blood donors",
"      </td>",
"      <td>",
"       0.2 to 0.5 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Shelter Island",
"      </td>",
"      <td>",
"       June 1978",
"       <sup>",
"        [7]",
"       </sup>",
"      </td>",
"      <td>",
"       Residents",
"      </td>",
"      <td>",
"       4.4 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       October 1978",
"       <sup>",
"        [7]",
"       </sup>",
"      </td>",
"      <td>",
"       Residents",
"      </td>",
"      <td>",
"       6.9 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       May 1998",
"       <sup>",
"        [8]",
"       </sup>",
"      </td>",
"      <td>",
"       Blood donors",
"      </td>",
"      <td>",
"       4.3 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       South Fork, Long Island",
"      </td>",
"      <td>",
"       Fall 1984",
"       <sup>",
"        [8]",
"       </sup>",
"      </td>",
"      <td>",
"       Blood donors",
"      </td>",
"      <td>",
"       15.8 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Eastern Long Island",
"      </td>",
"      <td>",
"       Winter 1994-95",
"       <sup>",
"        [9]",
"       </sup>",
"      </td>",
"      <td>",
"       Residents",
"      </td>",
"      <td>",
"       1 percent",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     1. Ruebush, TK, 2nd, Juranek, DD, Chisholm, ES, et al. Human babesiosis on Nantucket Island. Evidence for self-limited and subclinical infections. N Engl J Med 1977; 297:825.",
"     <br>",
"      2. Popovsky, MA, Lindberg, LE, Syrek, AL, Page, PL. Prevalence of Babesia antibody in a selected blood donor population. Transfusion 1988; 28:59.",
"      <br>",
"       3. Krause, PJ, Telford, SR, 3rd, Pollack, RJ, et al. Babesiosis: an underdiagnosed disease of children. Pediatrics 1992; 89:1045.",
"       <br>",
"        4. McQuiston, JH, Childs, JE, Chamberland, ME, Tabor, E. Transmission of tick-borne agents of disease by blood transfusion: a review of known and potential risks in the United States. Transfusion 2000; 40:274.",
"        <br>",
"         5. Krause, PJ, McKay, K, Gadbaw, J, et al. Increasing health burden of human babesiosis in endemic sites. Am J Trop Med Hyg 2003; 68:431.",
"         <br>",
"          6. Leiby, DA, Chung, AP, Gill, JE, et al. Demonstrable parasitemia among Connecticut blood donors with antibodies to Babesia microti. Transfusion 2005; 45:1804.",
"          <br>",
"           7. Filstein, MR, Benach, JL, White, DJ, et al. Serosurvey for human babesiosis in New York. J Infect Dis 1980; 141:518.",
"           <br>",
"            8. Linden, JV, Wong, SJ, Chu, FK, et al. Transfusion-associated transmission of babesiosis in New York State. Transfusion 2000; 40:285.",
"            <br>",
"             9. Hilton, E, DeVoti, J, Benach, JL, et al. Seroprevalence and seroconversion for tick-borne diseases in a high-risk population in the northeast United States. Am J Med 1999; 106:404.",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_36_14925=[""].join("\n");
var outline_f14_36_14925=null;
var title_f14_36_14926="Urea slant Shigella v Proteus";
var content_f14_36_14926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Shigella versus urease positive gram-negative rods on urea slant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 258px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urea slant shows the positive (pink) and negative (yellow) reactions that differentiate Proteus (left) from Shigella (right).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael S Glickman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_36_14926=[""].join("\n");
var outline_f14_36_14926=null;
var title_f14_36_14927="Assessing risk factors for hepatic steatosis in HIV";
var content_f14_36_14927=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Potentially modifiable factors that contribute to hepatic steatosis in HIV-infected patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 289px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: McGovern BH. Hepatic steatosis in HIV/HCV-coinfected patients: time to reevaluate! Gastroenterology 2011; 140:772. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_36_14927=[""].join("\n");
var outline_f14_36_14927=null;
